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1. INTRODUCTION 1 
 
Diabetes is a chronic condition that occurs when the body cannot produce enough 
insulin or cannot use insulin, and is diagnosed by observing raised levels of glucose in 
the blood. Insulin is a hormone produced in the pancreas; it is required to transport 
glucose from the bloodstream into the body’s cells where it is used as energy. The 
lack, or ineffectiveness, of insulin in a person with diabetes means that glucose 
remains circulating in the blood. Over time, the resulting high levels of glucose in the 
blood (known as hyperglycaemia) causes damage to many tissues in the body, leading 
to the development of disabling and life-threatening health complications. 
Prediabetes 
Before people develop type 2 diabetes or non-insulin dependent diabetes mellitus 
(NIDDM), they almost always have "prediabetes" blood glucose levels that are higher 
than normal but not yet high enough to be diagnosed as diabetes. Doctors sometimes 
refer to prediabetes as impaired glucose tolerance (IGT) or impaired fasting glucose 
(IFG), depending on what test was used when it was detected. This condition puts the 
patients at a higher risk for developing type 2 diabetes and cardiovascular disease. 
 Genetics of Type 2 Diabetes 
Type 2 diabetes has a stronger link to family history and lineage than type 1, although 
it too depends on environmental factors. Studies of twins have shown that genetics 
play a very strong role in the development of type 2 diabetes. Lifestyle also influences 
the development of type 2 diabetes. Obesity tends to run in families, and families tend 
to have similar eating and exercise habits. If you have a family history of type 2 
diabetes, it may be difficult to figure out whether your diabetes is due to lifestyle 
factors or genetic susceptibility. Most likely it is due to both. 
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1.1 HISTORY OF DIABETES MELLITUS 2,3,4 
Diabetes is one of the oldest known diseases. An Egyptian manuscript from c.1550 
BCE mentions the phrase "the passing of too much urine."The great Indian physician 
Sushruta (fl. 6th century BCE) identified the disease and classified it as Medhumeha. 
He further identified it with obesity and sedentary lifestyle, advising exercises to help 
"cure" it. The ancient Indians tested for diabetes by observing whether ants were 
attracted to a person's urine, and called the ailment "sweet urine disease" 
(Madhumeha).  
Concerning the sweetness of urine, it is to be noted that the Chinese, Japanese and 
Korean words for diabetes are based on the same ideographs which mean "sugar urine 
disease". It was in 1776 that Matthew Dobson confirmed that the sweet taste comes 
from an excess of a kind of sugar in the urine and blood.  
The first complete clinical description of diabetes was given by the Ancient Greek 
physician Aretaeus of Cappadocia (fl. 1st century CE), who noted the excessive 
amount of urine which passed through the kidneys and gave the disease the name 
"diabetes."  
Diabetes mellitus appears to have been a death sentence in the ancient era. 
Hippocrates makes no mention of it, which may indicate that he felt the disease was 
incurable. Aretaeus did attempt to treat it but could not give a good prognosis; he 
commented that "life (with diabetes) is short, disgusting and painful."  
In medieval Persia, Avicenna (980-1037) provided a detailed account on diabetes 
mellitus in The Canon of Medicine, "describing the abnormal appetite and the 
collapse of sexual functions," and he documented the sweet taste of diabetic urine. 
Like Aretaeus before him, Avicenna recognized a primary and secondary diabetes. He 
also described diabetic gangrene, and treated diabetes using a mixture of lupine, 
trigonella (fenugreek), and zedoary seed, which produces a considerable reduction in 
the excretion of sugar, a treatment which is still prescribed in modern times. Avicenna 
also "described diabetes insipidus very precisely for the first time", though it was later 
Johann Peter Frank (1745-1821) who first differentiated between diabetes mellitus 
and diabetes insipidus.  
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Although diabetes has been recognized since antiquity, and treatments of various 
efficacy have been known in various regions since the Middle Ages, and in legend for 
much longer, pathogenesis of diabetes has only been understood experimentally since 
about 1900.The discovery of a role for the pancreas in diabetes is generally ascribed 
to Joseph von Mering and Oskar Minkowski, who in 1889 found that dogs whose 
pancreas was removed developed all the signs and symptoms of diabetes and died 
shortly afterwards. ln 1910, Sir Edward Albert Sharpey-Schafer suggested that people 
with diabetes were deficient in a single chemical that was normally produced by the 
pancreas. He proposed calling this substance insulin, from the Latin insula, meaning 
island, in reference to the insulin-producing islets of Langerhans in the pancreas.  
Year 1910 
English physiologist Sir Edward Albert Sharpey-Schafer's study of the pancreas leads 
him to the discovery of a substance that would normally be produced in non-diabetics: 
insulin. The name comes from the Latin insula, meaning island, referencing 
the insulin-producing islets of Langerhans in the pancreas. 
Year 1916 
Elliott Joslin, MD, publishes the first edition of The Treatment of Diabetes Mellitus. 
A clinician and educator, Joslin is renowned throughout the world as one of the most 
influential voices in diabetes care. 
Year 1921 
Frederick Banting, MD, and his then student assistant, Charles Best, MD, extract 
insulin from dog pancreases. Banting and Best were working in laboratory space at 
the University of Toronto provided by Professor J.J.R. Macleod. They inject the 
insulin into dogs whose pancreases have been removed, and the animals’ 
blood sugar levels go down. James Collip purifies the extract so that it can be used in 
humans. Banting and Macleod were awarded the 1923 Nobel Prize in Physiology or 
Medicine, though the contributions of all four men have been recognized as important 
in the discovery of insulin. 
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Year 1923 
Eli Lilly and Company begins commercial production of insulin. In the decades that 
follow, manufacturers develop a variety of slower-acting insulins, the first being 
protamine insulin introduced by Novo Nordisk in 1936. 
Year 1924 
At a time when less than half of all babies born to mothers with diabetes survive, 
Priscilla White, MD, starts the Joslin Pregnancy Clinic. Fifty years later, Dr. White 
achieves a 90 percent survival rate among babies born to her patients. 
Year 1949 
Rachmiel Levine, MD, discovers that insulin works like a key, 
transporting glucose into cells. 
Year 1953 
Tablets for testing urine glucose become widely available, and urine test strips appear 
over the next few years. These options are simpler than using Benedict’s solution, 
which must be mixed with urine and heated over boiling water. 
Year 1955 
Sulfonylureas, oral medications that stimulate the pancreas to release more insulin, 
are available. New, more potent forms of these drugs will become available later. 
Year 1959 
Using radioimmunoassay technology, Solomon Berson, MD and Rosalyn Yalow, PhD 
develop a method for measuring insulin in the blood. They notice that some people 
with diabetes still make their own insulin, and they identify ―insulin-dependent‖ (type 
1) and ―non-insulin-dependent‖ (type 2) diabetes. 
Year 1961 
Glucagon, a hormone produced by the pancreas that raises glucose levels, is 
introduced by Eli Lilly and Company as a treatment for severe hypoglycemia. 
Year 1964 
The Ames Company introduces the first strips for testing blood glucose by color code. 
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Year 1966 
The first successful pancreas transplant is performed at the University of Minnesota 
Hospital. 
Year 1970 
The Ames Company introduces the first glucose meter. 
Year 1971 
Insulin receptors are discovered on cell membranes. This discovery raises the 
possibility that missing or defective insulin receptors may prevent glucose from 
entering the cells, thus contributing to the insulin resistance of type 2 diabetes. 
Year 1972 
The relationship between blood vessel disease and hyperglycemia is reported. 
U100 insulin is introduced. With the availability of this single concentration and with 
insulin syringes marked with only a U100 scale, frequency of dosing errors could be 
reduced. 
Year 1974 
Development of the Biostator enabled continuous glucose monitoring and closed loop 
insulin infusion. Human Leukocyte Antigens (HLAs) are discovered on cell surfaces. 
People with type 1 diabetes have specific patterns of HLA that are associated with 
varying levels of risk for diabetes. 
Year 1976 
The first insulin pumps were invented. 
Year 1977 
Rosalyn Yalow, PhD is awarded the Nobel Prize in Physiology and Medicine for her 
work in measuring insulin in the body. 
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Boston researchers develop a test to measure glycosylated hemoglobin 
(A1C). A1c testing becomes the gold standard for measuring long-term diabetes 
control. 
 
Year 1978 
Researchers at the City of Hope National Medical Center in Duarte, California, and 
Genentech, Inc., in San Francisco, induce E. coli bacteria to produce insulin identical 
to human insulin. Portable insulin pumps are introduced and researchers achieve 
normal blood glucose levels in patients using them. But, due to their large size, they 
are impractical at this time.The National Diabetes Information Clearing house is 
created by the federal government to gather and document all diabetes literature. 
Year 1979 
The National Diabetes Data Group develops a new diabetes classification system: 
1) insulin-dependent or type 1 diabetes, 2) non-insulin-dependent or type 2 diabetes,         
3) gestational diabetes, and 4) diabetes associated with other syndromes or conditions. 
Year 1980 
A new animal model of type 1 diabetes, the non-obese diabetic (NOD) strain of 
mouse is described in Japan. Introduction of the basal-bolus concept enabled 
"intensive insulin therapy" to be used in the clinic to effectively treat people with type 
1 diabetes. 
Year 1982 
The FDA approves human insulin produced by genetically altered bacteria. A 64K 
autoantibody is discovered and is found to be associated with type 1 diabetes. 
Year 1983 
A link between hypoglycemia and brain metabolism is established. Second-generation 
sulfonyl ureas enter the market allowing patients to take smaller doses and with 
reduced side effects. 
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Year 1984 
The insulin molecule is identified to be a target of autoimmune response in 
individuals with type 1 diabetes. 
Year 1985 
Scientists discover a relationship between pregnancy and the worsening of diabetic 
retinopathy. 
Year 1987 
The 64K autoantibody originally discovered in 1982 is found to be predictive of type 
1 diabetes. 
Year 1989 
Glucose is discovered to be distributed into muscle and fat cells via a transporter 
known as GLUT-4. Understanding how glucose is transported from the bloodstream 
into cells to be used as fuel is important to locating different drug targets that can 
improve insulin sensitivity. 
Year 1990 
The 64K autoantibody associated with type 1 diabetes is identified. This protein, 
GAD, or glutamate decarboxylase, is an important enzyme involved in cellular 
communication in the brain and pancreas. The immune system’s attack on GAD 
triggers a progressive autoimmune response that leads to diabetes. 
Year 1993 
The Diabetes Control and Complications Trial (DCCT) showed that keeping blood 
glucose levels as close to normal as possible slows the onset and progression of eye, 
kidney, and nerve diseases caused by diabetes. In fact, it demonstrated that any 
sustained lowering of blood glucose helps, even if the person has a history of poor 
control. 
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Year 1994 
Captopril is FDA approved to treat end-stage renal disease. Leptin, the fat cell 
hormone that modulates feeding behavior and hormone secretion, is cloned. 
The Scandinavian Simvastatin Survival Study (4S) showed that cholesterol lowering 
with statins markedly reduced the risk of myocardial infarction, stroke or death. The 
effect was greatest in individuals with diabetes. 
Mid-1990s 
The incretin hormone GLP-1 is discovered. Incretin hormones are secreted from the 
gut in response to food, and encourage the body to produce insulin. Discovery of 
GLP-1 will later lead to a new class of diabetes drugs that can increase insulin 
secretion in response to glucose, and even increase the amount of beta cells in the 
pancreas. 
Year 1995 
The drug metformin becomes available in the U.S. Metformin is a biguanide that 
prevents glucose production in the liver. 
Year 1996 
The drug acarbose, brand name Precose (Bayer Corporation) becomes available in the 
U.S. Acarbose is an alpha-glucosidase inhibitor that slows digestion of some 
carbohydrates. Lispro (a lysine-proline analog) is introduced by Eli Lilly and 
Company as the world’s fastest acting insulin. 
Year 1997 
Troglitazone, brand name Rezulin (Parke-Davis), is approved by the FDA. It is the 
first in a class of drugs known as thiazolidinediones, and it improves insulin 
sensitivity in muscle cells. It is eventually removed from the market due to liver 
toxicity. Rosiglitazone and pioglitazone, also in this drug class, are later brought on to 
the market. 
The terms ―insulin-dependent diabetes‖ (IDDM) and ―non-insulin-dependent 
diabetes‖ (NIDDM) had long been used to describe different groups of diabetes 
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patients. The terms type 1 diabetes and type 2 diabetes are now accepted to define 
diabetes by cause rather than treatment. In addition, the fasting glucose level for 
diagnosing diabetes is lowered from 140 mg/dl to 126 mg/dl. 
Year 1998 
Repaglinide, brand name Prandin (Novo Nordisk) is developed. Repaglinide belongs 
to a class of drugs known as meglitinides. They stimulate insulin secretion in the 
presence of glucose. 
The United Kingdom Prospective Diabetes Study (UKPDS) shows that people with 
type 2 diabetes who practice tight control of blood sugar levels and blood 
pressure levels reduce their risk of complications, similar to the results of the DCCT 
in people with type 1 diabetes. Together these two studies transform the nature of 
diabetes care around the world. 
Year 2002 
Treatment with the anti-CD3 monoclonal antibody, hOKT3 gamma1(Ala-Ala), slows 
the deterioration of insulin production and improves metabolic control during the first 
year of type 1 diabetes in the majority of patients. 
The American Diabetes Association defines prediabetes as impaired fasting glucose 
(IFG) and/or impaired glucose tolerance (IGT). IFG is defined as a fasting blood 
glucose of 100-125 mg/dl, and IGT is defined as a glucose level from 140 mg/dl – 
199 mg/dl two hours after consuming a glucose-rich drink. Later, A1c levels of 5.7% 
to 6.4% are also used to identify individuals with prediabetes. 
Year 2005 
Exenatide, brand name Byetta, is approved in the U.S. as a first-in-class incretin 
mimetic (GLP-1) drug to treat type 2 diabetes. An injectable drug, exenatide works by 
increasing insulin production in response to blood glucose levels. 
Pramlintide, brand name Symlin, is approved in the U.S. as an injectable adjunct 
treatment for people who use insulin at mealtimes but still fail to achieve desirable 
glucose levels. 
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Year 2006 
FDA approves JANUVIA (sitagliptin phosphate), the first in a new class of drugs 
known as DPP-4 inhibitors that enhance the body's ability to lower elevated blood 
sugar. DPP-4 is an enzyme that naturally blocks GLP-1 from working, so by 
inhibiting this enzyme, GLP-1 works in the gut to promote insulin secretion. 
Year 2008 
The results of the ACCORD, ADVANCE and VADT studies are published and 
presented at the American Diabetes Association Scientific Sessions. All three studies 
fail to show a benefit of intensive glycemic control on cardiovascular outcomes in 
people with type 2 diabetes who are at high cardiovascular risk. The results from 
these studies lead to clinical recommendations that call for a more individualized 
approach for setting glycemic goals and treatment targets. 
Year 2013 
FDA approves Invokana (Canagliflozin), the first in a new class of drugs know as the 
SGLT-2 inhibitors, for lowering elevated blood sugar in patients with type 2 diabetes. 
SGLT-2 inhibitors block the activity of sodium glucose transport proteins in the 
kidney, reducing glucose re-uptake and increasing secretion of glucose in the urine. 
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1.2   EPIDEMIOLOGY 10 
International occurrence 
Type 2 diabetes mellitus is less common in non-Western countries where the diet 
contains fewer calories and daily caloric expenditure is higher. However, as people in 
these countries adopt Western lifestyles, weight gain and type 2 diabetes mellitus are 
becoming virtually epidemic. 
Rates of diabetes are increasing worldwide. The International Diabetes Federation 
predicts that the number of people living with diabetes will to rise from 366 million in 
2011 to 552 million by 2030. In the United States, the prevalence of diagnosed 
diabetes has more than doubled in the last 3 decades, largely because of the increase 
in obesity. 
The top 10 countries in number of people with diabetes are currently India, China, the 
United States, Indonesia, Japan, Pakistan, Russia, Brazil, Italy, and Bangladesh. The 
greatest percentage increase in rates of diabetes will occur in Africa over the next 20 
years. Unfortunately, at least 80% of people in Africa with diabetes are undiagnosed, 
and many in their 30s to 60s will die from diabetes there. 
Race-related demographics 
The prevalence of type 2 diabetes mellitus varies widely among various racial and 
ethnic groups. The image below shows data for various populations. Type 2 diabetes 
mellitus is more prevalent among Hispanics, Native Americans, African Americans, 
and Asians/Pacific Islanders than in non-Hispanic whites. Indeed, the disease is 
becoming virtually pandemic in some groups of Native Americans and Hispanic 
people. The risk of retinopathy and nephropathy appears to be greater in blacks, 
Native Americans, and Hispanics. 
Age-related demographics 
Type 2 diabetes mellitus occurs most commonly in adults aged 40 years or older, and 
the prevalence of the disease increases with advancing age. Indeed, the aging of the 
population is one reason that type 2 diabetes mellitus is becoming increasingly 
common. Virtually all cases of diabetes mellitus in older individuals are type 2. 
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In addition, however, the incidence of type 2 diabetes is increasing more rapidly in 
adolescents and young adults than in other age groups. The disease is being 
recognized increasingly in younger persons, particularly in highly susceptible racial 
and ethnic groups and the obese. In some areas, more type 2 than type 1 diabetes 
mellitus is being diagnosed in prepubertal children, teenagers, and young adults. The 
prevalence of diabetes mellitus by age is shown in the image below. 
Prevalence of diabetes in India according to IDF in 2015 
• India is home to the second largest number of adults living with diabetes 
worldwide, after China. 
• India is home to the second largest number of children with type 1 diabetes in 
the world (70,200), after the USA, and accounts for the majority of the 
children with type 1 diabetes in the region. 
India is the largest contributor to regional mortality, with one million deaths 
attributable to diabetes. 
Prevalence in south India 
• Prevalence of Diabetes among both urban as well as the rural Indians, with 
southern India having the sharpest increase. 
• Indian Council of Medical Research (ICMR) has completed the phase -1 of 
task force project-ICMR-India Diabetes (INDIAB) Study- Phase- 1 includes 
the rural and urban settings of Tamilnadu, Jharkhand , Maharashtra, and 
Chandigarh. 
• The adjusted prevalence of Diabetes    
• Tamilnadu 10.4%     
• Jharkhand  5.3%     
• Chandigarh  13.6%  
• Maharashtra 
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1.3    DIABETES – CLASSIFICATION 5-9 
• Type 1 diabetes: results from the body's failure to produce insulin, and 
presently requires the person to inject insulin. (Also referred to as insulin-
dependent diabetes mellitus, IDDM for short, and juvenile diabetes.)  
• Type 2 diabetes: results from insulin resistance, a condition in which cells fail 
to use insulin properly, sometimes combined with an absolute insulin 
deficiency. (Formerly referred to as non-insulin-dependent diabetes mellitus, 
NIDDM for short, and adult-onset diabetes.)  
• Gestational diabetes: is when pregnant women, who have never had diabetes 
before, have a high blood glucose level during pregnancy. It may preceed 
development of type 2 DM.  
Other forms of diabetes mellitus include congenital diabetes, which is due to genetic 
defects of insulin secretion, cystic fibrosis-related diabetes, steroid diabetes induced 
by high doses of glucocorticoids, and several forms of monogenic diabetes.  
All forms of diabetes have been treatable since insulin became available in 1921, and 
type 2 diabetes may be controlled with medications. Both type 1 and 2 are chronic 
conditions that usually cannot be cured. Pancreas transplants have been tried with 
limited success in type 1 DM; gastric bypass -surgery has been successful in many 
with morbid obesity and type 2 DM. Gestational diabetes usually resolves after 
delivery. Diabetes without proper treatments can cause many complications. Acute 
complications include hypoglycemia, diabetic ketoacidosis, or nonketotic 
hyperosmolar coma. Serious long-term complications include cardiovascular disease, 
chronic renal failure, retinal damage. Adequate treatment of diabetes is thus 
important, as well as blood pressure control and lifestyle factors such as smoking 
cessation and maintaining a healthy body weight.  
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1.4     ETIOLOGIC CLASSIFICATION OF DIABETES MELLITUS6,9,11,12 
I Type 1 diabetes (β-cell destruction, usually leading to absolute insulin 
deficiency)  
a. Immune mediated  
b. Idiopathic  
II Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly secretory defect with insulin 
resistance)  
III Other specific types  
a. Genetic defects of n-cell function  
i. Chromosome 12, HNF- 1 α (MODY3)  
ii. Chromosome  7, glucokinase (MODY2) 
iii. Chromosome 20, HNF-4 α (MODY1) 
iv. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4)  
v. Chromosome 17, HNF-1 β (MODY5)  
vi. Chromosome 2, Neuro D1 (MODY6) 
vii. Mitochondrial DNA  
viii. Others  
b. Genetic defects in insulin action  
i. Type A insulin resistance  
ii. Leprechaunism 
iii. Rabson-Mendenhall syndrome  
iv. Lipoatrophic diabetes  
v. Others 
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c. Diseases of the exocrine pancreas  
i. Pancreatitis  
ii. Trauma/pancreatectomy 
iii. Neoplasia 
iv. Cystic fibrosis  
v. Hemochromatosis  
vi. Fibrocalculous pancreatopathy 
vii. Others  
d. Endocrinopathies 
i. Acromegaly  
ii. Cushing's syndrome  
iii. Glucagonoma 
iv. Pheochromocytoma 
v. Hyperthyroidism  
vi. Somatostatinoma 
vii. Aldosteronoma 
viii. Others  
e. Drug- / Chemical-induced 
i. Vacor 
ii. Pentamidine 
iii. Nicotinic acid  
iv. Glucocorticoids  
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v. Thyroid hormone  
vi. Diazoxide 
vii. β -adrenergic agonists 
viii. Thiazides  
ix. Dilantin  
x. α -Interferon 
xi. Others 
f. Infections  
i. Congenital rubella  
ii. Cytomegalovirus  
iii. Others  
g. Uncommon forms of immune-mediated diabetes  
i. ―Stiff-man‖ syndrome  
ii. Anti-insulin receptor antibodies  
iii. Others  
h. Other genetic syndromes sometimes associated with diabetes  
i. Down's syndrome  
ii. Klinefelter's syndrome  
iii. Turner's syndrome  
iv. Wolfram's syndrome  
v. Friedreich's ataxia  
vi. Huntington's chorea  
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vii. Laurence-Moon-Biedl syndrome 
viii. Myotonic dystrophy  
ix. Porphyria  
x. Prader-Willi syndrome  
xi. Others 
IV Gestational diabetes mellitus (GDM) 
i. Type 1 diabetes (β-cell destruction, usually leading to absolute 
insulin deficiency) 
V Immune-mediated diabetes 
VI Idiopathic diabetes 
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J 
1.5      CAUSES15 
 
The cause of diabetes depends on the type. Type 1 diabetes is partly inherited and 
then triggered by certain infection
,
, with some evidence pointing at Coxsackie B4 
virus. There is a genetic element it individual susceptibility to some of these 
triggers which has been traced to particular HLA genotypes (i.e., the genetic 
―self‖ identifiers relied upon by the immune system). However, even in those who 
have inherited the susceptibility type I diabetes mellitus seem to require an 
environmental trigger. Type 2 diabetes is due primarily to lifestyle factors and 
genetics.  
Table 1 
Comprehensive list of other causes of diabetes  
 
 
 
 
 Genetic defects of (β-cell Function 
o Maturity-onset diabetes of 
young (MODY) 
o Mitochondrial DNA mutations 
 
 Genetic defects in insulin 
processing or 
insulin action 
o Defects in proinsulin conversion 
o Insulin gene mutations 
o Insulin receptor mutations 
 
 Exocrine Pancreatic Defects 
o Chronic pancreatitis 
o Pancreatectomy 
o Pancreatic neoplasia 
o Cystic fibrosis 
o Hemochromatosis 
o Fibrocalculous pancreatopathy 
 Endocrinopathies 
o Growth hormone excess  
(acromegaly) 
o Cushing syndrome 
o Hyperthyroidism 
o Pheochromocytoma 
o Glucagonoma 
 
 Infections 
 
o Cytomegalovirus infection 
o Coxsackievirus B 
 
 Drugs 
o Glucocorticoids 
o Thyroid hormone 
o β-adrenergic agonists 
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1.6   COMPARISON OF TYPE 1 AND 2 DIABETES 
12 
Table 2 
Most cases of diabetes mellitus fall into three broad categories: type 1, type 2, 
and gestational diabetes. A few other types are described. The term diabetes, 
usually refers to diabetes mellitus. The rare disease  diabetes insipidus  has similar 
symptoms as diabetes mellitus, but without disturbances in the sugar metabolism 
(insipidus meaning "without taste" in Latin). 
The term "type 1 diabetes" has replaced several former terms, including childhood-
onset diabetes, juvenile diabetes, and insulin-dependent diabetes mellitus (IDDM). 
Likewise, the term "type 2 diabetes" has replaced several former terms, including 
adult-onset diabetes, obesity-related diabetes, and non-insulin dependent diabetes 
mellitus (NIDDM). Beyond these two types, there is no agreed-upon standard 
nomenclature. Various sources have defined "type 3 diabetes" as: gestational 
diabetes, insulin-resistant type 1 diabetes (or "double diabetes"), type 2 diabetes 
which has progressed to require injected insulin, and latent autoimmune diabetes of 
adults (or LADA or "type 1.5" diabetes).  
Feature Type 1 diabetes Type 2 diabetes 
Onset Sudden Gradual 
Age at onset Any age (mostly 
young) 
Mostly in adults 
Body status Thin or normal Often obese 
Ketoacidosis Common Rare 
Autoantibodies Usually present Absent 
Endogenous insulin Low or absent Normal, decreased 
or increased 
Concordance in 
identical twins 
50% 90% 
Prevalence 10% 90% 
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Type 1 diabetes  
Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of 
the islets of Langerhans in the pancreas leading to insulin deficiency. This type of 
diabetes can be further classified as immune-mediated or idiopathic. The majority of 
type 1 diabetes is of the immune-mediated nature, where beta cell loss is a T-cell 
mediated autoimmune attack. There is no known preventive measure against type 1 
diabetes, which causes approximately 10% of diabetes mellitus cases in North 
America and Europe. Most affected people are otherwise healthy and of a healthy 
weight when onset occurs. Sensitivity and responsiveness to insulin are usually 
normal, especially in the early stages. Type 1 diabetes can affect children or adults but 
was traditionally termed "juvenile diabetes" because it represents a majority of the 
diabetes cases in children.  
"Brittle" diabetes, also known as unstable diabetes or labile diabetes, is a term that 
was traditionally used to describe to dramatic and recurrent swings in glucose levels, 
often occurring for no apparent reason in insulin-dependent diabetes. This term, 
however, has no biologic basis and should not be used. There are many different 
reasons for type 1 diabetes to be accompanied by irregular and unpredictable 
hyperglycemias, frequently with ketosis, and sometimes serious hypoglycemia, 
including an impaired counter regulatory response to hypoglycemia, occult infection, 
gastroparesis (which leads to erratic absorption of dietary carbohydrates), and 
endocrinopathies (eg, Addison's disease). These phenomena are believed to occur no 
more frequently than in 1% to 2% of persons with type 1 diabetes. 
Type 2 diabetes  
Type 2 diabetes mellitus is characterized by insulin resistance which may be 
combined with relatively reduced insulin secretion. The defective responsiveness of 
body tissues to insulin is believed to involve the insulin receptor. However, the 
specific defects are not known. Diabetes mellitus due to a known defect are classified 
separately. Type 2 diabetes is the most common type.  
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In the early stage of type 2 diabetes, the predominant abnormality is reduced insulin 
sensitivity. At this stage hyperglycemia can be reversed by a variety of measures and 
medications that improve insulin sensitivity or reduce glucose production by the liver.  
Figure 1 
PATHOPHYSIOLOGY OF NIDDM 
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Gestational diabetes  
Gestational diabetes mellitus (GDM) resembles type 2 diabetes in several respects, 
involving a combination of relatively inadequate insulin secretion and responsiveness. 
It occurs in about 2%-5% of all pregnancies and may improve or disappear after 
delivery. Gestational diabetes is fully treatable but requires careful medical 
supervision throughout the pregnancy. About 20%-50% of affected women develop 
type 2 diabetes later in life.  
Even though it may be transient, untreated gestational diabetes can damage the health 
of the fetus or mother. Risks to the baby include macrosomia (high birth weight), 
congenital cardiac and central nervous system anomalies, and skeletal muscle 
malformations. Increased fetal insulin may inhibit fetal surfactant production and 
cause respiratory distress syndrome. Hyperbilirubinemia may result from red blood 
cell destruction. In severe cases, perinatal death may occur, most commonly as a 
result of poor placental perfusion due to vascular impairment. Labor induction may be 
indicated with decreased placental function. A cesarean section may be performed if 
there is marked fetal distress or an increased risk of injury associated with 
macrosomia, such as shoulder dystocia. 
Other types  
Pre-diabetes indicates a condition that occurs when a person's blood glucose levels are 
higher than normal but not high enough for a diagnosis of type 2 diabetes.  
Latent autoimmune diabetes of adults is a condition in which Type I diabetes 
develops in adults. Adults with LADA are frequently initially misdiagnosed as having 
Type 2 diabetes, based on age rather than etiology.  
Some cases of diabetes are caused by the body's tissue receptors not responding to 
insulin (even when insulin levels are normal, which is what separates it from type 2 
diabetes); this form is very uncommon. Genetic mutations (autosomal or 
mitochondrial) can lead to defects in beta cell function. Abnormal insulin action may 
also have been genetically determined in some cases. Any disease that causes 
extensive damage to the pancreas may lead to diabetes (for example, chronic 
pancreatitis and cystic fibrosis). Diseases associated with excessive secretion of 
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insulin-antagonistic hormones can cause diabetes (which is typically resolved once 
the hormone excess is removed). Many drugs impair insulin secretion and some 
toxins damage pancreatic beta cells. The ICD-10 (1992) diagnostic entity, 
malnutrition-related diabetes mellitus (MRDM or MMDM, ICD-10 code E12), was 
deprecated by the World Health Organization when the current taxonomy was 
introduced in 1999. 
Diabetic emergencies  
People (usually with type 1 diabetes) may also present with diabetic ketoacidosis, a 
state of metabolic dysregulation characterized by the smell acetone; a rapid, deep 
breathing known as Kussmaul breathing; nausea: vomiting and abdominal pain: and 
altered states of consciousness.  
A rare but equally severe possibility is hyperosmolar nonketotic state, which is more 
common in type 2 diabetes and is mainly the result of dehydration. 
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1.7 COMPLICATIONS OF DIABETES MELLITUS 13,14 
All forms of diabetes increase the risk of long-term complications. These typically 
develop after many years (10-20), but may be the first symptom in those who have 
otherwise not received a diagnosis before that time. The major long-term 
complications relate to damage to blood vessels. Diabetes doubles the risk of 
cardiovascular disease. The main "macrovascular" diseases (related to atherosclerosis 
of larger arteries) are ischemic heart disease (angina and myocardial infarction), 
stroke and peripheral vascular disease.  
Diabetes also causes "microvascular" complications—damage to the small blood 
vessels. Diabetic retinopathy, which affects blood vessel formation in the retina of the 
eye, can lead to visual symptoms, reduced vision, and potentially blindness. Diabetic 
nephropathy, the impact of diabetes on the kidneys, can lead to scarring changes in 
the kidney tissue, loss of small or progressively larger amounts of protein in the urine, 
and eventually chronic kidney disease requiring dialysis. Diabetic neuropathy is the 
impact of diabetes on the nervous system, most commonly causing numbness, 
tingling and pain in the feet and also increasing the risk of skin damage due to altered 
sensation. Together with vascular disease in the legs, neuropathy contributes to the 
risk of diabetes-related foot problems (such as diabetic foot ulcers) that can be 
difficult to treat and occasionally require amputation. 
1. Acute Diabetic ketoacidosis (DKA): 
Another acute complication more likely to occur in the IDDM ketoacidosis, is a 
condition caused by a lack of insulin leading to build-up ketoacids. Ketones are one of 
the natural by-products of fat metabolism. Excessive ketone bodies are formed by the 
biochemical imbalance in uncontrolled or poorly managed diabetes. The condition 
known as diabetic ketoacidosis can directly cause an acute life-threatening event, a 
diabetic coma. The signs include nausea and vomiting which can lead to loss of water 
from the body, stomach pain, and deep and rapid breathing. Other signs are a flushed 
face, dry skin and mouth, a fruity breath odour, a rapid and weak pulse, and low blood 
pressure. If the person is not given fluids and insulin right away, ketoacidosis can lead 
to coma and even death.  
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2.Vascular 
a. Microvascular 
 i. Retinopathy 
ii. Neuropathy 
 iii. Nephropathy  
b. Macrovascular 
i. Heart disease leading to heart attacks due to high cholesterol level, and  
smoking (CAD) 
ii. Stroke  
iii.Peripheral vascular disease which cause other complications like ulcers,  
gangrene, and amputation 
a) Microvascular 
i. Retinopathy: 
Changes occurring in the eye which are distinctive of diabetes involve the 
narrowing, hardening, bulging, haemorrhaging or severing of the veins and 
capillaries of the retina. This is a serious complication known as retinopathy and 
may lead to loss of vision. Visual changes in the earlier stages may include 
diminished vision, contraction of the visual field, changes in the size of objects of 
photophobia. In the more advanced stage, termed 'proliferative retinopathy. 
haemorrhages, retinal detachment and other serious forms of deterioration are 
observed. When the disease progresses to this late stage total blindness ma y 
occur. 
It usually takes between 10-13 years for diabetic retinopathy to develop and it is 
present in some degree in most diabetics who have had the disease for 21 years. In 
only about half of the diabetics who develop it however, is vision markedly 
impaired and blindness occurs in only about 6%. Still, diabetes is the. leading 
cause of blindness in adults 20 to 74 years old and is estimated to cause from 
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12,000 to 24,000 new cases each year. Two other complications of diabetes. 
Cataracts and glaucoma, can also lead to loss of vision. 
The development of laser therapy will probably reduce the prevalence o f 
diabetes-induced blindness; however this therapy is not without occasional side 
effects (haemorrhage, retinal detachment and loss of visual field) and is therefore 
indicated only for the more serious conditions. 
ii. Neuropathy: 
Diabetic neuropathy results in damage to the nerves. 
Neuropathy Classified as: 
a. Peripheral neuropathy 
b. Autonomic neuropathy 
Diabetic neuropathies are among the most frequent complication of long term 
diabetes. It is estimated that 60% to 70% of diabetics have mild to severe forms 
of nervous system damage. The femoral nerve is commonly involved  giving 
rise to symptoms in the legs and feet. Pain is the chief symptom and tends to 
worsen at night when the person is at rest. It is usually relieved by activity and 
aggravated by cold. Paraesthesias are a common accompaniment of the pain. 
Cramping, tenderness and muscle weakness also occur but atrophy is rare. 
Advanced femoral nerve disease is a major contributing cause of lower extremity 
amputations. Nerves in the arms, abdomen and back may also be affected. 
Symptoms may include impaired heart function, slowed digestion, reduced or 
absent perspiration, severe oedema, carpal tunnel syndrome, alternating bouts of 
diarrhoea and constipation, bladder atony, urinary and faecal incontinence and 
impotence. 
With respect to sexual impotence, diabetes is probably the single most 
common disease associated with erectile failure (termed neurogenic impotence in 
the diabetic). Since diabetes is a metabolic disease with vascular and nervous 
system complications and an erection involves all levels of the nervous system 
from the brain to the peripheral nerves, lesions anywhere along the path may be 
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responsible for erectile failure. It has been estimated that close to 50% of diabetic 
males have some degree of erectile dysfunction. Neuropathies usually improve 
with the control of the diabetes. Severe or chronic changes may require 
several weeks or months to show maximum improvement.  
 
iii. Nephropathy: 
Nephropathy is a common and important accompaniment of diabetes and one 
that in young diabetics takes precedence over heart disease as a cause of illness 
and death. As with eye changes, there is a wide variation in the type and degree of 
renal damages. Nephropathy is less frequent than retinopathy and where it occurs 
is also a development of long standing diabetes. Nevertheless, diabetes is the 
leading cause of end-stage renal disease in the US, accounting for about 40% of 
new cases. In 1995, a total of 98,872 people with diabetes underwent dialysis or 
kidney transplantation and 27,851 developed end-stage renal disease. 
One study reported that among 200 juvenile diabetics who survived 20years 
after onset, one half had evidence of renal disease. Like other long-term 
complications, good blood glucose control goes a long way towards reducing 
the risk of diabetic nephropathy. In addition to monitoring the blood sugar 
levels periodic monitoring of a diabetic patients kidney function (blood urea 
nitrogen uric acid, creatinine and  clearance) is important. 
 
b) Macro vascular: 
Diabetes  i s  a  major  r i sk  f or  morbidi ty and  morta l i t y through  
atherosclerosis. Coronary and cerebrovascular disease is 2 -4 times more 
common in a diabetic. 
Atherosclerosis is a main macrovascular disease. It is extremely common in 
the community and it's prevalence like diabetes is rapidly increased in our 
country. The indicating factor for atherosclerosis is deposition of excessive blood 
cholesterol in the arterial wall. 
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Ischemic heart disease: 
The arteries supplying improper blood to heart, due to this atherosclerosis may 
result in insufficiency or complete blockage of blood supply. This may lead to 
chest pain or discomfort or heaviness usually in central pain of chest. Rest 
relieves angina, sometimes angina starts even at rest and this is a more dangerous 
variety sometimes patient develop heart attack subsequently, particularly if they 
do not take care. 
Cerebrovascular disease: 
Atherosclerosis reduces the blood supply to brain. Due to decrease in blood 
supply the major blood vessels of brain lead to cerebro vascular disease. Paralytic 
stroke is one of the common manifestation of cerebrovascular disease. Patient with 
diabetes are 2-4 times more likely to suffer from stroke than non-diabetic. 
Stroke: 
Disease caused by damage to blood vessels in the brain. Depending on the part of 
the brain affected, a stroke can cause a person to lose the ability to speak or move 
a part of the body such as an arm or a leg. Usually only one side of the body is 
affected. 
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1.8  DIAGNOSIS16,17 
Diabetes diagnostic criteria 
Table 3 
Condition 
2 hour glucose 
mmol/l(mg/dL) 
Fasting glucose 
mmol/1(mg/dL) 
Glycated 
hemoglobin 
% 
Normal <7.8 (<140) <6.1 (<110) <6.0 
Impaired fasting 
glycaemia 
 
<7.8 (<140) 
&
<
7
.
0
(
<
l
 
2
6
) 
6.1(110) 
& 
<7.0(<126) 
 
6.0-6.4 
Impaired glucose 
tolerance 
7.8 (>140) <7.0 (<126) 6.0-6.4 
Diabetes mellitus 11.1 (>200) 7.0 (>126) 6.5 
 
Diabetes mellitus is characterized by recurrent or persistent 
hyperglycemia, and is diagnosed by demonstrating any one of the 
following: 
 Fasting plasma glucose level  7.0 mmol/L (126 mg/dL).  
 Plasma glucose  11.1 mmol/L (200 mg/dL) two hours after a 7 5 
gm Oralglucose load as in a glucose tolerance test. 
 Symptoms of  hypergl ycemia  and  casual  p lasma glucose                
 11 .1mmol/L (200 mg/dL). 
 Glycated hemoglobin (HbA1c) 6.5%. 
 
A positive result, in the absence of unequivocal hyperglycemia, should be confirmed 
by a repeat of any of the above-listed methods on a different day. It is preferable to 
measure a fasting glucose level because of the ease of measurement and the 
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considerable time commitment of formal glucose tolerance testing, which takes two 
hours to complete and offers no prognostic advantage over the fasting test. 
According to the current definition, two fasting glucose measurements above126 
mg/dL(7.0 mmol/L) is considered diagnostic for diabetes mellitus. 
 
People with fasting glucose levels  from 100 to 125 mg/ dL(5.6 to  6.9 
mmol/L) are considered to have impaired fasting glucose. Patients with 
plasma glucose at or above 140 mg/dL (7.8 mmol/L), but not over 200 mg/dl 
(11.1 mmol/L), two hours after a 75 gm oral glucose load are considered to have 
impaired glucose tolerance. Of these two pre-diabetic states, the latter in 
particular is a major risk factor for progression to full -blown diabetes 
mellitus as well as cardiovascular disease. 
 
Glycated hemoglobin is better than fasting glucose for determining risks of  
cardiovascular disease and death from any cause. 
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2. DRUG TREATMENT OF DIABETES MELLITUS 18 
 
 
Pharmacologic therapy of type 2 diabetes has changed dramatically in the last 10 
years, with new drugs and drug classes becoming available. These drugs allow for the 
use of combination oral therapy, often with improvement in glycemic control that was 
previously beyond the reach of medical therapy. 
Agents used in diabetic therapy include the following: 
a. Biguanides 
b. Sulfonylureas 
c. Meglitinide derivatives 
d. Alpha-glucosidase inhibitors 
e. Thiazolidinediones (TZDs) 
f. Glucagonlike peptide–1 (GLP-1) agonists 
g. Dipeptidyl peptidase IV (DPP-4) Inhibitors 
h. Selective sodium-glucose transporter-2 (SGLT-2) inhibitors 
i. Insulins 
j. Amylinomimetics 
k. Bile acid sequestrants 
l. Dopamine agonists 
Traditionally, diet modification has been the cornerstone of diabetes management. 
Weight loss is more likely to control glycemia in patients with recent onset of the 
disease than in patients who are significantly insulinopenic. Medications that induce 
weight loss, such as orlistat, may be effective in highly selected patients but are not 
generally indicated in the treatment of the average patient with type 2 diabetes 
mellitus. 
Patients who are symptomatic at initial presentation with diabetes may require 
transient treatment with insulin to reduce glucose toxicity (which may reduce beta-
cell insulin secretion and worsen insulin resistance) or an insulin secretagogue to 
rapidly relieve symptoms such as polyuria and polydipsia. 
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2.1 ORAL HYPOGLYCAEMIC DRUGS 
18-22 
 
i. BIGUANIDES: 
These agents are considered the first choice for oral type 2 diabetes treatment. They 
reduce hyperglycemia by decreasing hepatic gluconeogenesis (primary effect) and 
increasing peripheral insulin sensitivity (secondary effect). They do not increase 
insulin levels or cause weight gain. Alone, they rarely cause hypoglycemia. 
Metformin 
Metformin is used as monotherapy or in combination with sulfonylureas, 
thiazolidinediones, or insulin. It is taken with food to minimize adverse GI effects. 
Metformin is available in immediate-release and extended-release formulations, as 
well as in combination with other antidiabetic drugs. 
Metformin is contraindicated in patients with impaired renal function, as indicated by 
a serum creatinine level of greater than 1.5 mg/dL in men or of more than 1.4 mg/dL 
in women, or an estimated GFR of less than 60 mL/min. It also should not be used 
within 48 hours of IV iodinated contrast medium.  
ii. SULFONYLUREAS: 
Sulfonylureas are time-honored insulin secretagogues (ie, oral hypoglycemic agents). 
They have been used as monotherapy and in combination with other oral 
hypoglycemic agents or with insulin, although glimepiride is the only sulfonylurea 
approved by the FDA for combination therapy. Sulfonylureas function by stimulating 
the release of insulin from pancreatic beta cells and can usually reduce HbA1c by 1-
2% and blood glucose concentrations by about 20%. 
Glyburide (DiaBeta
®
, Glynase
®
) 
Glyburide is a second-generation sulfonylurea. It is more potent and exhibits fewer 
drug interactions than first-generation agents. It also has a longer half-life than most 
sulfonylureas., Glyburide has been used as an alternative to insulin for the treatment 
of gestational diabetes, although it is not FDA approved for this indication.  
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Glipizide (Glucotrol
®
, Glucotrol XL
®
, Glipizide XL
®
) 
Glipizide is also a second-generation sulfonylurea. It is more potent and exhibits 
fewer drug interactions than first-generation agents. It may cause more physiologic 
insulin release with less risk for hypoglycemia and weight gain than other 
sulfonylureas. 
Glimepiride (Amaryl
®
) 
Stimulates insulin secretion from beta cells; may also decrease rate of hepatic glucose 
production and increase insulin receptor sensitivity. 
iii. MEGLITINIDE DERIVATIVES: 
Meglitinides are much more short-acting insulin secretagogues than sulfonylureas. 
Preprandial dosing potentially achieves more physiologic insulin release and less risk 
for hypoglycemia. Meglitinide monotherapy has efficacy similar to that of 
sulfonylureas. 
Repaglinide (Prandin
®
) 
Repaglinide is probably most useful in patients at increased risk for hypoglycemia 
who still need an insulin secretagogue. It works by stimulating insulin release from 
pancreatic beta cells. Better control of postprandial glycemic excursions also may be 
achieved with repaglinide. It is FDA approved for monotherapy and for combination 
therapy with metformin or thiazolidinediones. 
Nateglinide (Starlix
®
) 
Nateglinide mimics endogenous insulin patterns, restores early insulin secretion, and 
controls mealtime glucose surges. It works by stimulating insulin release from 
pancreatic beta cells. It is indicated as monotherapy for type 2 diabetes or as 
combination therapy with metformin or a thiazolidinedione. Nateglinide is available 
in 60-mg and 120-mg tablets. 
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iv.   ALPHA-GLUCOSIDASE INHIBITORS: 
Alpha-glucosidase inhibitors prolong the absorption of carbohydrates and thus help to 
prevent postprandial glucose surges. Their induction of flatulence greatly limits their 
use. Doses of these agents should be titrated slowly to reduce GI intolerance. Their 
effect on glycemic control is modest, affecting primarily postprandial glycemic 
excursions. 
Acarbose (Precose
®
) 
Acarbose was the first alpha-glucosidase inhibitor approved by the FDA. It is 
absorbed to a small degree, so liver function abnormalities can occur rarely. It can be 
used as monotherapy or in combination with other treatment modalities. The modest 
effect of acarbose on glycemia and its high degree of GI adverse effects (flatulence) 
limit its use. 
Miglitol (Glyset
®
) 
Miglitol is not absorbed, so liver function abnormalities do not occur. It is FDA 
approved for use as monotherapy or in combination with sulfonylureas. Its modest 
effect on glycemia and high degree of GI adverse effects (flatulence) limit its use. 
v. THIAZOLIDINEDIONES: 
Thiazolidinediones reduce insulin resistance in the periphery (ie, they sensitize 
muscle and fat to the actions of insulin) and perhaps to a small degree in the liver (ie, 
insulin sensitizers, antihyperglycemics). They activate peroxisome proliferator–
activated receptor (PPAR) gamma, a nuclear transcription factor that is important in 
fat cell differentiation and fatty acid metabolism. The major action of 
thiazolidinediones is probably actually fat redistribution. These drugs may have beta-
cell preservation properties. Thiazolidinediones have moderate glycemic efficacy, 
between that of alpha-glucosidase inhibitors and sulfonylureas. 
Pioglitazone (Actos
®
) 
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic 
control. It improves target-cell response to insulin without increasing insulin secretion 
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from the pancreas. It also increases insulin-dependent glucose use in skeletal muscle 
and adipose tissue. Pioglitazone lowers triglycerides more than rosiglitazone, 
probably because of its PPAR-alpha effect. 
Long duration of pioglitazone use and high cumulative doses have been linked with 
slightly increased risk for bladder cancer. The FDA currently recommends not 
prescribing pioglitazone for patients with active bladder cancer and using it with 
caution in patients with a history of bladder cancer. 
Rosiglitazone (Avandia
®
) 
Rosiglitazone is an insulin sensitizer with a major effect on the stimulation of glucose 
uptake in skeletal muscle and adipose tissue. It lowers plasma insulin levels. It is 
indicated for type 2 diabetes associated with insulin resistance, as monotherapy and in 
conjunction with sulfonylureas and/or metformin and insulin. It may preserve beta-
cell function and yields positive effects on vasculature and inflammation. It changes 
LDL and HDL particle size. Because of data suggesting an elevated risk of 
myocardial infarction in patients treated with rosiglitazone, this agent is currently 
available only via a restricted access program. Patients currently taking rosiglitazone 
and benefiting from the drug are permitted to continue using it if they choose to do so. 
Rosiglitazone is available to new patients only if they are unable to achieve glucose 
control on other medications and are not willing to take pioglitazone, the only other 
thiazolidinedione. 
iv. GLUCAGON LIKE PEPTIDE-1 AGONISTS: 
Glucagonlike peptide–1 (GLP-1) agonists mimic the endogenous incretin GLP-1, 
stimulating glucose-dependent insulin release (as opposed to oral insulin 
secretagogues, which may cause non–glucose-dependent insulin release and 
hypoglycemia), reducing glucagon, and slowing gastric emptying. 
Exenatide (Byetta
®
, Bydureon
®
) 
Exenatide is a GLP-1 agonist that improves glycemic control in patients with type 2 
diabetes mellitus. Like endogenous incretins, it enhances glucose-dependent insulin 
secretion by pancreatic beta cells, suppresses inappropriately elevated glucagon 
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secretion, and slows gastric emptying. The drug's 39–amino acid sequence partially 
overlaps that of the human incretin GLP-1. 
Exenatide is indicated as adjunctive therapy to improve glycemic control in patients 
with type 2 diabetes who have not achieved glycemic control with metformin or a 
sulfonylurea. The solution is administered by subcutaneous injection twice daily. 
Liraglutide (Victoza
®
) 
Liraglutide is a once-daily injectable GLP-1 receptor agonist that stimulates G-protein 
in pancreatic beta cells. It increases intracellular cyclic adenosine monophosphate 
(cAMP), leading to insulin release in the presence of elevated glucose concentrations. 
Liraglutide is indicated as an adjunct to diet and exercise to improve glycemic control 
in adults with type 2 diabetes mellitus. The drug has not been studied in combination 
with insulin. 
Albiglutide (Tanzeum
®
) 
Albiglutide is a once-weekly GLP-1 receptor agonist indicated as an adjunct to diet 
and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It 
may be used with other antidiabetic agents, although a dose reduction may be needed 
for insulin secretagogues (eg, sulfonylureas) or insulin if co-administered. GLP-1 
receptor agonists augment glucose-dependent insulin secretion. 
Dulaglutide (Trulicity
®
) 
Dulaglutide is a glucagonlike peptide-1 (GLP-1) agonist that acts as an incretin 
mimetic. It increase insulin secretion in the presence of elevated blood glucose, delays 
gastric emptying to decrease postprandial glucose, and decreases glucagon secretion. 
It is administered as a once-weekly SC injection. It is indicated as an adjunct to diet 
and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
 
v. DIPEPTIDYL PEPTIDASE IV (DPP 4) INHIBITORS: 
Incretin hormones are part of an endogenous system involved in the physiologic 
regulation of glucose homeostasis. They increase insulin release and decrease 
glucagon levels in the circulation in a glucose-dependent manner. DPP-4 degrades 
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numerous biologically active peptides, including the endogenous incretins GLP-1 and 
glucose-dependent insulinotropic peptide (GIP). DPP-4 inhibitors prolong the action 
of incretin hormones. 
Sitagliptin (Januvia
®
) 
Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 
activity in vitro at concentrations approximating those from therapeutic doses. 
Sitagliptin can be used as a monotherapy or in combination with metformin or a 
thiazolidinedione. It is given once daily and is weight neutral. 
Saxagliptin (Onglyza
®
) 
Saxagliptin inhibits DPP-4 and thereby increases concentrations of GLP-1 and GIP, 
which stimulate insulin release in response to increased blood glucose levels 
following meals. This action enhances glycemic control. Saxagliptin is indicated as an 
adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes 
mellitus. 
Linagliptin (Tradjenta
®
) 
Linagliptin is a DPP-4 inhibitor that increases and prolongs incretin hormone activity. 
It is indicated for adults with type 2 diabetes mellitus, along with diet and exercise, to 
lower blood glucose levels. It may be used as monotherapy or in combination with 
other common antidiabetic medications, including metformin, sulfonylurea, or 
pioglitazone; it has not been studied in combination with insulin. 
Alogliptin (Nesina
®
) 
Selective dipeptidyl peptidase-4 (DPP-4) inhibitor; slows inactivation of incretin 
hormones (eg, GLP-1, GIP), thereby reducing fasting and postprandial glucose 
concentrations in a glucose-dependent manner. 
viii. AMYLINOMIMETICS: 
These agents mimic endogenous amylin effects by delaying gastric emptying, 
decreasing postprandial glucagon release, and modulating appetite. 
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Pramlintide (Symlin
®
, SymlinPen 120
®
, SymlinPen 60
®
) 
This agent is a synthetic analogue of human amylin, a naturally occurring hormone 
made in pancreatic beta cells. It slows gastric emptying, suppresses postprandial 
glucagon secretion, and regulates food intake because of centrally mediated appetite 
modulation. 
Pramlintide is indicated for the treatment of type 1 or type 2 diabetes in combination 
with insulin. It is administered before mealtime in patients who have not achieved 
desired glucose control despite optimal insulin therapy. 
ix. SODIUM-GLUCOSE TRANSPORTER-2 (SGLT2) INHIBITORS: 
Figure 2 
Role of SGLT1 and SGLT2 enzymes in the reabsorption of glucose in the kidney 
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SGLT2 inhibitors lower the renal glucose threshold and around 90% of glucose in the 
renal filtrate thereby gets excreted. 
Canagliflozin (Invokana
®
) 
Canagliflozin, an SGLT-2 inhibitor, lowers the renal glucose threshold (ie, the plasma 
glucose concentration that exceeds the maximum glucose reabsorption capacity of the 
kidney). Lowering the renal glucose threshold results in increased urinary glucose 
excretion. 
Dapagliflozin (Farxiga
®
) 
Dapagliflozin reduces glucose reabsorption in the proximal renal tubules and lowers 
the renal threshold for glucose, thereby increasing urinary glucose excretion. It is 
indicated as an adjunct to diet and exercise to improve glycemic control in type 2 
diabetes mellitus. It is indicated as monotherapy, as initial therapy with metformin, or 
as an add-on to other oral glucose-lowering agents, including metformin, 
pioglitazone, glimepiride, sitagliptin, and insulin. 
Empagliflozin (Jardiance
®
) 
Empagliflozin, a SGLT2 inhibitor, decreases blood glucose by increasing urinary 
glucose excretion. SGLT-2 is expressed in the proximal renal tubules and is 
responsible for the majority of the reabsorption of filtered glucose from the tubular 
lumen. SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold 
for glucose. 
x. BILE ACID SEQUESTRANTS: 
Colesevelam is FDA approved as an adjunctive therapy to improve glycemic control 
in adults with type 2 diabetes mellitus. 
Colesevelam (WelChol
®
) 
Colesevelam is a high-capacity bile acid sequestrant. It is indicated as an adjunct to 
diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
The precise mechanism by which colesevelam improves glycemic control is largely 
unknown. 
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ORAL AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS  
Table: 1 
 
S.No. 
Drug class 
Mechanism  
of action 
Daily  
dosage(mg) Frequency  
Per day 
Duration of  
action  
(hrs) 
Main side effects contraindications 
Mode of  
Excretion 
1 SULFONYLUREA (SU) 
A First generation 
 Chlorpropamide  100-500 1 24-60 Antabuse like reaction, 
highest 
Incidence of hypoglycaemia 
Avoid in elderly Urine 
 Tolbutamide  500-2500 2-3 6-12 Urine 
 Acetoxamide  250-500 2-3 16 Urine 
 Tolazamide  100-500 2-3 24 Urine 
B Second generation 
 Glipizide Increase 
insulin 
secretion 
2..5-20 1-3 8-12 
Hypoglycaemia, 
Weight gain 
Moderate to severe liver 
dysfunction; adjust dose in 
severe kidney 
dysfunction, avoid use of 
glyburide in elderly patients or 
patients with kidney dysfunction 
Urine 50%  
Bile 50% 
 Glyburide 
2.5-20 1-3 8-12 
Urine 50%  
Bile 50% 
 Glimepiride 
1-8 1 16-24 
Urine 60%  
Bile 40% 
 Glipenclamide 
2.5-20 1-2 16-24 
Urine 50%  
Bile 50% 
 Gliclazide 
80-320 1-2 16-24 
Urine 50%  
Bile 20% 
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S.No Drug class Mechanism of  action Daily dosage(mg) 
Frequency  
Per day 
Dura t io n  o f   
action  
(hrs) 
Main side effects contraindications  
Mo de of   
Excretion 
2 NON –SULFONYLUREA 
A Short acting insulin secretogogues 
 Repaglinide Acute increase of  
insulin secretion 
1-6 2-3 2-4 Hypoglycaemia,  
Weight gain. 
Severe liver or kidney 
dysfunction;  
Avoid concomitant use 
of repaglinide with 
gemfibrosil 
Bile 
Bile 
120-360 2-3 2-4 
 Nateglinide 
B Biguanides 
 Metformin Increases liver and  
muscle insulin  
sensitivity, decreases  
Hepatic glucose  
production 
250-2500 2-4 8-12 Gastrointestinal,  
Lactic acidosis(rare) 
Moderate to severe liver or 
cardiac dysfunction, mild 
renal dysfunction 
Urine 90%  
Bile 10% 
Urine 90%  
Bile 10%  Metformin ER    
Urine 
   
 Phenformin 
C Thiazolidinediones 
 Rosiglitazone Increases adipose and  
muscle insulin  
sensitivity 
2-8 1-2 12-24 Weight gain, edema, 
anemia, Pulmonary 
edema, congestive heart 
failure 
Malabsorption syndrome, 
cholestasis 
Urine 
Urine 
15-45 1 24 
 Pioglitazone 
D Alpha glucosidase inhibitors 
 Acarbose Delays intestinal  
carbohydrate  
absorption 
25 mg once daily,  
titrated to 100 mg 3  
times daily 
1-3 4 Gastrointestinal Irritable bowel syndrome,  
severe kidney or liver  
dysfunction. 
Faeces 
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2.2  SODIUM GLUCOSE CO-TRANSPORTER TYPE 2 (SGLT2) 
INHIBITORS
23,29
 
Although hyperglycaemia is a key therapeutic focus in the management of patients 
with type 2 diabetes mellitus (T2DM), many patients experience sub-optimal 
glycaemic control. Current glucose-lowering agents involve the targeting of various 
body organ. Sodium glucose co-transporter type 2 (SGLT2) inhibitors target the 
kidney, reduce renal glucose elimination, thus lowering glucose blood levels. 
Glucose reabsorption in the kidney 
Overview of renal structure and function 
The main structural and functional unit of the kidney is the nephron. A normal human 
kidney contains approximately 1 million nephrons, with the majority located in the 
renal cortex and the remainder situated near the cortico-medullary junction. Each 
nephron consists of a glomerulus, containing afferent and efferent capillaries, and a 
renal tubule, which includes the glomerular (or Bowman’s) capsule, proximal 
convoluted tubule, loop of Henle, distal convoluted tubule, and the collecting duct. 
Higher positive pressure in the glomerular blood vessels forces fluid and solutes from 
the plasma into the glomerular capsule (filtration), and this filtrate then flows through 
the renal filtrate tubule. Much of this glomerular filtrate undergoes reabsorption into 
capillary blood via the proximal convoluted tubule. Nitrogenous and other waste 
products largely remain in the filtrate and pass into the collecting duct, eventually 
leading to urinary excretion. Other substances (e.g., hydrogen ions, potassium ion, 
ammonia, and drugs) undergo transport from peritubular capillaries into the renal 
tubule cells, and then into the filtrate for ultimate urinary excretion via the ureter, 
bladder, and urethra. 
Physiology of renal glucose transport 
Key kidney function that help achieve glucose homeostasis involve renal 
gluconeogenesis, glucose uptake from the circulation, and glucose reabsorption from 
the glomerular filtrate. Given an average plasma glucose concentration of 
approximately 100 mg/dL (5.5 mmol/L) and a normal glomerular filtration rate of 
approximately 180 L/day, healthy individuals filter in the region of 180g/day of 
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glucose. Virtually all glucose is reabsorbed in the proximal convoluted tubule and 
returned to the circulation, so that effectively no glucose is excreted in the urine of an 
otherwise healthy individual. This system is highly efficient and allows conservation 
of glucose, which is a valuable energy source. 180 g/day of glucose reabsorbed, and 
the fact that the kidney produce 15-55 g/day of glucose via gluconeogenesis and 
metabolize 25-35 g/day, renal absorption is a primary mechanism by which the 
kidney influences glucose homeostasis. 
To retrieve glucose in the filtrate, the kidney utilizes two types of membrane-bound 
carrier proteins:  SGLTs (sometimes described as symporters because they transport 
both glucose and sodium) and the facilitated glucose transporters (GLUTs, sometimes 
described as uniporters because they only transport glucose).Reabsorption of glucose 
from the glomerular filtrate is mediated by SGLTs in the proximal convoluted tubule, 
in a process that is independent of insulin. Approximately 90% of filtrated renal 
glucose is reabsorbed in the first segment (S1) of the proximal convoluted tubule by 
SGLT2, a low-affinity high-capacity transporter, and the remaining 10% is removed 
in the distal segment (S3) by SGLT1, a high-affinity low-capacity transporter. In the 
kidney, SGLT2 and SGLT1 are located on the luminal surface of epithelial cells 
lining the proximal convoluted tubule.SGLT2 is expressed to a lower extent in other 
organs, including the liver, while SGLT1is extensively expressed in the small 
intestine, where it has significant role in glucose absorption.  
SGLTs actively transport glucose against its concentration gradient via coupling to 
the electrochemical sodium gradient, using energy from a sodium/phosphate 
adenosine triphosphatase pump. Glucose is released from the proximal convoluted 
tubule and returned to the blood stream via GLUT2 in the s1/s2 segment and via 
GLUT1 in the s3 segment of the proximal convoluted tubule. This is a passive process 
requiring no energy input. 
The amount of glucose filtered in the kidney increases linearly with increasing plasma 
glucose concentration until the transport maximum for glucose(TMG) beyond the level 
of the (TMG ), the glucose transport system becomes saturated, therefore any excess 
glucose remains in the filtrate and is excreted in the urine(ie., glucosuria). In healthy, 
glucose-tolerant individuals, TMG  is equivalent to a filtration rate of 260-350 mg/min 
SGLT2 Inhibitors in NIDDM  Page 44 
 
The plasma glucose concentration at which TMG is reached is called the renal 
threshold, and occurs at approximately 200mg/dL  (11.0 mmol/L). 
Targeting renal glucose reabsorption with SGLT2 inhibitors 
Inhibiting SGLT2 provides an attractive addition to the DM treatment 
armamentarium. SGLT2 inhibitors reduce the TMG , so less glucose is reabsorbed in 
the proximal convoluted tubule, they also lower plasma glucose concentration. The 
net result is increased UGE and decreased hyperglycemia. In addition to potentially 
improving hyperglycemic symptoms and DM disease complications , normalization 
of plasma glucose concentration may improve the adverse effects of glucotoxicity, 
which may contribute to DM itself, by reducing insulin resistance, decreasing hepatic 
gluconeogenesis, and potentially improving pancreatic beta-cell function. 
SGLT2 INHIBITORS 
Phlorizin is a naturally occurring glucoside found in various plants, such as the root 
bark of apple and other fruit trees, and was the prototype SGLT2 inhibitor. First 
isolated in the 1800s, research into Phlorizin provided the evidence that altered renal 
glucose excretion could improve glycaemic control. Studied from the 1950s revealed 
that Phlorizin blocked sugar transport in several tissues, including the kidney and 
small intestine, and this was subsequently found to be due to inhibition of SGLT 
protein. Phlorizin was ultimately found to be a competitive inhibitor of SGLT1 and 
SGLT2, but with a great affinity for SGLT2. In the 1980s, investigators found that 
Phlorizin-induced UGE was effective in reducing hyperglycaemia via an insulin-
independent mechanism, without causing hyperglycaemia. Animal studies also 
supported the use of Phlorizin in improving insulin sensitivity without affecting 
insulin action in healthy control animals, with hyperglycaemia and insulin resistance 
both returning after Phlorizin was unsuitable for clinical development as a therapeutic 
agent for a number of reasons.  
Firstly, Phlorizin has a low selectivity for SGLT2 versus SGLT1, resulting in the 
inhibition of SGLT1 as well as SGLT2. AsSGLT1 is primarily expressed in the small 
intestine, where it is responsible for the absorption of glucose and galactose from the 
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diet, SGLT1 inhibition can result in gastrointestinal side effect such as severe 
diarrhoea, dehydration, and malabsorption.  
Secondly Phlorizin has a low oral bioavailability and is metabolized to Phloretin by 
glucosidase enzymes in the gut, which means it must be given, which may lead to 
interference with glucose uptake in various tissues (Eg., the central nervous system) 
.The first reported SGLT2 inhibitor was T-1095, an orally administered O-glycoside 
pro-drug that was metabolised in the liver into its active form T-1095A. Its non-
selective SGLT1 inhibition led to discontinuation. Then attention turned to the C-
glycoside compounds which had the increased metabolic stability. 
Figure 3 
Mechanism of Action of SGLT2 Inhibitors 
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Drugs in the SGLT2 inhibitors class include empagliflozin, canagliflozin, 
dapagliflozin, ipragliflozin (which has not yet been approved for use in the U.S.). At 
this time canagliflozin is the only drug in this class approved by the FDA for the 
treatment of type 2 diabetes. 
Vaginal yeast infections and urinary tract infections are the most common side effects 
associated with canagliflozin with the greatest risk being in female patients and those 
men who are uncircumcised. 
There is also an increased desire to urinate and the medication is not indicated in 
patients with type 1 diabetes, or patients with frequent ketones in their blood or urine, 
severe renal impairment, end stage renal disease or patients receiving dialysis. 
Patients should be advised to expect glucose to be in the urine and if they are using 
urine glucose strips that they will have a positive reading most of the time. 
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2.3   INSULINS 
30,31
 
Human Insulin and Insulin Analogs are available for insulin replacement therapy. 
Insulins also are classified by the timing of their action in your body – specifically, 
how quickly they start to act, when they have a maximal effect and how long they act. 
Insulin analogs have been developed because human insulins have limitations when 
injected under the skin. In high concentrations, such as in a vial or cartridge, human 
(and also animal insulin) clumps together. This clumping causes slow and 
unpredictable absorption from the subcutaneous tissue and a dose-dependent duration 
of action (i.e. the larger dose, the longer the effect or duration). In contrast, insulin 
analogs have a more predictable duration of action. The rapid acting insulin analogs 
work more quickly, and the long acting insulin analogs last longer and have a more 
even, ―peakless‖ effect. 
Insulin has been available since 1925. It was initially extracted from beef and pork 
pancreases. In the early 1980’s, technology became available to produce human 
insulin synthetically. 
Characteristics of Insulin 
Insulins are categorized by differences in: 
 Onset (how quickly they act) 
 Peak (how long it takes to achieve maximum impact) 
 Duration (how long they last before they wear off) 
 Concentration (Insulins sold in the U.S. have a concentration of 100 units per 
ml or U100. In other countries, additional concentrations are available. Note: 
If you purchase insulin abroad, be sure it is U100.) 
 Route of delivery (whether they are injected under the skin or given 
intravenously) 
 Insulin is usually injected into the fatty tissue just under the skin. This is also 
called subcutaneous tissue. 
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Types of Insulin : There are three main groups of insulins: 
 Fast-acting 
 Intermediate-acting 
 Long-acting insulin. 
Fast-acting insulin: 
 Is absorbed quickly from your fat tissue (subcutaneous) into the bloodstream. 
 Is used to control the blood sugar during meals and snacks and to correct high 
blood sugars 
Includes: 
Rapid Acting Insulin Analogs (Insulin Aspart, insulin Lyspro, Insulin Glulisine) 
which have an onset of action of 5 to 15 minutes, peak effect in 1 to 2 hours and 
duration of action that lasts 4-6 hours. With all doses, large and small, the onset of 
action and the time to peak effect is similar, The duration of insulin action is, 
however, affected by the dose – so a few units may last 4 hours or less, while 25 or 30 
units may last 5 to 6 hours. As a general rule, assume that these insulins have duration 
of action of 4 hours. 
Regular Human Insulin 
Includes 
Humulin or Novolin which has an onset of action of 1/2 hour to 1 hour, peak effect in 
2 to 4 hours, and duration of action of 6 to 8 hours. The larger the dose of regular the 
faster the onset of action, but the longer the time to peak effect and the longer the 
duration of the effect. 
Intermediate-acting insulin: 
 Is absorbed more slowly, and lasts longer 
 Is used to control the blood sugar overnight, while fasting and between meals 
Includes: 
NPH Human Insulin which has an onset of insulin effect of 1 to 2 hours, a peak effect 
of 4 to 6 hours, and duration of action of more than 12 hours. Very small doses will 
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have an earlier peak effect and shorter duration of action, while higher doses will have 
a longer time to peak effect and prolonged duration. 
Pre-Mixed Insulin  
Includes 
 Humulin 70/30 
 Novolin 70/30 
 Novolog 70/30 
 Humulin 50/50 
 Humolog mix 75/25 
which is NPH pre-mixed with either regular human insulin or a rapid- acting insulin 
analog. The insulin action profile is a combination of the short and intermediate acting 
insulins. 
Long-acting insulin: 
 Is absorbed slowly, has a minimal peak effect, and a stable plateau effect that 
lasts most of the day. 
 Is used to control the blood sugar overnight, while fasting and between meals 
Includes: 
Long acting insulin analogs (Insulin Glargine, Insulin Detemir) which have an onset 
of insulin effect in 1 1/2-2 hours. The insulin effect plateaus over the next few hours 
and is followed by a relatively flat duration of action that lasts 12-24 hours for insulin 
detemir and 24 hours for insulin glargine. 
Ultralong-acting insulin analogue 
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was 
developed by Novo Nordisk under the brand name Tresiba. It is administered via 
subcutaneous injection once daily to help control the blood sugar level of those with 
diabetes. It has a duration of action that lasts up to 40 hours (compared to 18 to 26 
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hours provided by other marketed long-acting insulins such as insulin glargine and 
insulin detemir), making insulin degludec a once-daily basal insulin for all patients. 
Figure 4 
 
2.4 MISCELLANEOUS DRUGS 
Antiparkinsonian Agents - Dopamine Agonists: 
Quick-release bromocriptine acts on circadian neuronal activities within the 
hypothalamus to reset the abnormally elevated hypothalamic drive for increased 
plasma glucose, triglyceride, and free fatty acid levels in fasting and postprandial 
states in patients with insulin resistance. 
Bromocriptine (Cycloset
®
)This quick- release formulation is the only bromocriptine 
product indicated for type 2 diabetes mellitus. It is indicated as an adjunct to diet and 
exercise to improve glycemic control. 
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3. BLOOD GLUCOSE PARAMETERS 36,37,38 
a. Glycated Hemoglobin (HbA1c) 
Glycated hemoglobin (glycosylated hemoglobin, hemoglobin A1c, HbA1C, A1C, 
or Hb1c; sometimes also HbA1c) is a form of hemoglobin used primarily to identify 
the average plasma glucose concentration over prolonged periods of time. It is 
formed in a non-enzymatic glycation pathway by hemoglobin's exposure to 
plasma glucose. Normal levels of glucose produce a normal amount of glycated 
hemoglobin. As the average amount of plasma glucose increases, the fraction of 
glycated hemoglobin increases in a predictable way. This serves as a marker for 
average blood glucose levels over the previous months prior to the measurement. 
 
The red blood cells of all individuals contain hemoglobin, which is 
responsible for carrying oxygen through the bloodstream. When hemoglobin 
combines with glucose (sugar), a molecule called glycosylated hemoglobin, or 
Hemoglobin A1c (HbA1c), is formed. Since everyone has glucose in their blood, all 
individuals also have glycosylated hemoglobin in their blood (usually between 3 
and 5 percent of blood). 
The amount of A1c in red blood cells is proportional to the amount or 
concentration of glucose in the blood, and to the age of the red blood cells. (The 
average red blood cell lives approximately 120 days, with new ones replacing 
dying red blood cells continuously. Accordingly, healthy individuals have a 
mixture of "young" and "old" red blood cells at all times.) 
If an individual has high blood-sugar levels, such as exists in poorly controlled 
or untreated diabetes mellitus, the glycosylated hemoglobin percentage will be 
elevated. Since it is also related to the "age" of the red blood cells, the 
glycosylated hemoglobin percentage will correspond to the average glucose level 
over the previous two to three months. This average level is in contrast to a 
routine measurement of the blood-sugar level, which reflects any food intake over 
the previous twelve hours. 
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Clinical Usefulness 
In diabetes mellitus, the blood sugar is elevated in the fasting state, with levels 
exceeding 126 milligrams per deciliter (mg/dL). Persistently elevated blood-
glucose levels result in many chronic complications, such as kidney failure, blindness, 
and poor circulation in the legs, which can result in amputation. 
Underlying Principle: 
In the normal 120-day lifespan of the red blood cell, glucose molecules react with 
hemoglobin, forming glycated hemoglobin. In individuals with poorly controlled 
diabetes, the quantities of these glycated hemoglobins are much higher than in healthy 
people. 
Once a hemoglobin molecule is glycated, it remains that way. A buildup of 
glycated hemoglobin within the zed cell, therefore, reflects the average level of glucose 
to which the cell has been exposed during its life-cycle. Measuring glycated 
hemoglobin assesses the effectiveness of therapy by monitoring long term serum 
glucose regulation. The HbA1c level is proportional to average blood glucose 
concentration over the previous four weeks to three months. Some researchers 
state that the major proportion of its value is related to a rather shorter period of 
two to four weeks. 
The 2010 American Diabetes Association Standards of Medical Care in 
Diabetes added the A1c> 6.5% as another criterion for the diagnosis of diabetes, 
but this is controversial and has not been universally adopted. 
The chart below shows the average daily blood glucose levels for four different 
HbA1c values. HbA1c Value averages daily blood glucose level over past three 
months. 
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Table 5 
Normal values of HbA1c 
 
  
The HbA1c test should be done every three to six months, depending on the 
patient’s treatment program and level of control. It's a good idea to discuss the 
HbA1c test with your doctor or diabetes educator, then, when you find out your 
HbA1cvalue, you'll know whether you are on target, or whether you need to 
work with your physician or diabetes educator on better control of your diabetes. 
 
b. Fasting Plasma Glucose (FPG) 
This test checks the patient’s fasting blood glucose levels. Fasting means after not 
having anything to eat or drink (except water) for at least 8 hours before the test. This 
test is usually done first thing in the morning, before breakfast. 
Diabetes is diagnosed at fasting blood glucose of greater than or equal to 126 mg/dL 
Table 6 
Normal values of Fasting Plasma Glucose 
 
  
 
 
 
 
 
 
Result A1c 
Normal < 5.7% 
Prediabetes 5.7% to 6.4% 
Diabetes >6.5% 
Result 
Fasting Plasma Glucose 
(FPG) 
Normal less than 100 mg/dL 
Prediabetes 100 mg/dL to 125 mg/dL 
Diabetes 126 mg/dL or higher 
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c. Oral Glucose Tolerance Test (also called the OGTT) 
The OGTT is a two-hour test that checks your blood glucose levels before and 2 hours 
after you drink a special sweet drink. It tells the doctor how your body processes 
glucose. 
Diabetes is diagnosed at 2 hour blood glucose of greater than or equal to 200 mg/dL 
Table 7 
Normal values of Oral Glucose Tolerance Test 
 
  
 
 
 
d. Random (also called Casual) Plasma Glucose Test 
This test is a blood check at any time of the day when you have severe diabetes 
symptoms. 
Diabetes is diagnosed at blood glucose of greater than or equal to 200 mg/dL 
 
 
 
 
 
 
Result 
Oral Glucose Tolerance 
Test (OGTT) 
Normal less than 140 mg/dl 
Prediabetes 140 mg/dl to 199 mg/dl 
Diabetes 200 mg/dl or higher 
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4. BODY MASS INDEX 32-35 
The body mass index (BMI), or Quetelet index, is a heuristic proxy for human 
body fat based on an individual's weight and height. BMI does not actually measure 
the percentage of body weight. It was invented between 1830 and 1850 by the 
Belgian polymath Adolph quetelet during the course of developing "social physics". 
Body mass index is defined as the individual's body weight divided by the square 
of his or her height. The formulae universally used in medicine produce a unit of 
measure of kg/m
2
. 
The healthy weight range is based on a measurement known as the body mass 
index (BMI).this can be determined by using weight and height of a person.  
BMI can be used to indicate if the patients are overweight, obese, underweight or 
normal. It will, however, over estimate fatness in people who are muscular or 
athletics Scientists and researchers have found the BMI to be a valuable tool in the 
study of obesity, diabetes and heart disease. Early diagnosis of a poor BMI can 
potentially aid in the prevention of disease and provide advanced warning of any 
health problem. 
Body mass index (BMI) is one of the most accurate ways to determine when 
extra pounds translate into health risks. BMI is a measure which takes into account 
a person's weight and height to gauge total body fat in adults. Someone with a 
BMI of 26 to 27 is about 20 present over weight, which is generally believed 
to carry moderate health risks. A BMI of 30 and higher is considered obese. The 
higher the BMI, the greater the risk of developing additional health problems. 
Obesity and diabetes: 
Diabetes is spreading worldwide as an epidemic. Diabetes is a disorder in which 
the body cells fail to take up glucose from the blood. Wasting of tissues is seen as 
glucose-starved cells are forced to consume their own proteins. Diabetes is the 
cause for blindness, kidney failure and amputation in adults. Individuals with 
diabetes lack the ability to use the hormone insulin. 
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As we start eating food, our body starts producing insulin. The insulin signal 
attaches to a special receptor on the cell surface, to make the cell turn-on its own 
glucose transporting machinery. It had been observed that type 2 diabetics have 
normal or even elevated levels of insulin in their body with normal insulin receptor 
but, due to some unknown reason, the binding of insulin to the cell receptors 
does not starts the glucose transporting machinery, which it is supposed to do. 
Special proteins called IRS (insulin receptor substrate) are inside the cell. In type 2 
diabetes something is interfering with the action of the IRS protein and it is also 
estimated that about 80% of those who develop type 2 diabetes are obese. When 
insulin attaches to the receptor protein, the receptor responds by adding a chemical 
called a phosphate group onto the IRS molecules due to which the IRS molecules 
turn into action. Once activated, they start variety of processes, including an 
enzyme that turns on the glucose transporter machinery. 
Overweight and obesity are both labels for series of weight, greater than what is 
generally considered healthy for an individual. BMI ranges for children and teens 
above a normal weight have different labels (at risk of overweight and overweight). 
Excess body weight is implicated as a risk factor for many disorders including heart 
disease, cancer, diabetes, female infertility, prostate enlargement, uterine fibroids, 
gallstone and gestational diabetes etc. The location of fat deposits in the body 
leads to different risks associated with it. Increased abdominal fat can be estimated 
by waist size. Dozens of controlled clinical trials were carried out to determine the 
effect of weight loss on fasting blood glucose. They found: 
 Weight loss produced by lifestyle modification declines blood glucose 
levels and HbA1c in type 2 diabetis. 
 Glucose tolerance can be improved in overweight individuals by 
decreasing abdominal fat. 
 Glucose tolerance can also be improved in overweight individuals with 
increased cardio respiratory fitness. 
In 1995, the U.S. national institute of health and the American health 
foundation issued new guidelines that define healthy weight as a BMI below 25.  
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Table  8 
 
 
 
 
 
 
 
Calculation of BMI: 
Using following formula to find BMI 
Mass (kg) 
BMI = 
Height (m) 
2
 
Table  9 
S.NO WEIGHT STATUS WOMEN MEN 
1 Anorexia < 17.5 < 17.5 
2 Under weight < 19.1 < 20.7 
3 In normal range 19.1-25.8 20.7-26.4 
4 Marginally overweight 25.8-27.3 26.4-27.8 
5 Over weight 27.3-32.3 27.8-31.1 
6 Very over weight 
or Obese 
>32.3 >31.1 
7 Severely obese          35-40 35-40 
8 Morbidly obese         40-50 40-50 
9 Super obese         50-60 50-60 
 
Weight status 
 
Body mass index in Kg/ m
2 
 Underweight 
 
 
17-18.4 
Normal 
 
 
18.5-24.9 
Overweight                          25.0-29.9 
Obese class1 30.0 -34.9 
Obese class II 
 
35-39.9 
Obese class III >  40 
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5. DRUG PROFILE 39-46 
1. METFORMIN39 
General description: 
Metformin is an oral antidiabetic drug in the biguanide class. It is the firstline drug 
of choice for the treatment of type 2 diabetes. 
Chemical data 
ChemicalFormula : C4H11N5 
Molecular Mass : 129.164 g/mol(free) 
165.63 g/mol(HCL) 
Chemical Name : N,N-dimethylimido dicarbonimidicdiamide 
Chemical structure: 
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Mechanism of action 
Metformin improves hyperglycemia primarily through its suppression of hepatic 
glucose production (hepatic gluconeogenesis) the average person with type 2 
diabetes has three times the normal rate of gluconeogenesis metformin treatment 
reduces this by over one third. Metformin activates AMP-activated protein kinase 
(AMPK),a liver enzyme that plays an important role in insulin signaling, whole 
body energy balance, and the metabolism of glucose and fats ; activation of AMPK is 
required for metfomin's inhibitory effect on the production of glucose by liver 
cells. Research published in 2008 further elucidated metformin's mechanism of 
action, showing that activation of AMPK is required for an increase in the 
expression of SHP, which in turn inhibits the expression of the hepatic 
gluconeogenic genes PEPCK and Glc-6-Pase.metformin is frequently used in 
research along with AICAR as an AMPK agonist. The mechanism by which 
biguanides increase the activity of AMPK remains uncertain; however, research 
suggests that metformin increases the amount of cystolic AMP (as opposed to a 
change in total AMP or total AMP/ATP) 
In addition to suppressing hepatic glucose production, metformin increases insulin 
sensitivity, enhances peripheral glucose uptake (by phosphorylating GLUT-4 
enhancer factor), increases fatty acid oxidation. and decreases absorption of 
glucose from the gastrointestinal tract. Increased peripheral utilization of 
glucose may be due to improved insulin binding to insulin receptors. 
Pharmacokinetics; 
Absorption: 
Metformin has an oral bioavailability of 50-60% under fasting conditions, and 
is absorbed slowly. 
Distribution: 
Peak plasma concentrations (C m a x) are reached within one to three 
hours of  taking immediate-release metformin and four to eight hours with 
extended-release formulations. The plasma protein binding of metformin is 
negligible, as reflected by its very high apparent volume of distribution (300-1000 
L after a single dose). Steady state is usually reached in one or two days. 
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Metabolism: 
Metformin is not metabolized. It is cleared from the body by tubular 
secretion and excreted unchanged in the urine; metformin is undetectable in blood 
plasma within 24 hours of a single oral dose. 
Excretion: 
The average elimination half life in plasma is 6.2 hours. Metformin is distributed 
to (and appears to accumulate in) red blood cells, with a much longer elimination half-
life: 17.6 hours. 
Contraindications : 
Metformin is contraindicated in patients with: 
1) Renal disease or renal dysfunction (e.g., as suggested by serum creatinine 
levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females] or abnormal creatinine 
clearance), which may also result from conditions such as cardiovascular 
collapse (shock), acute myocardial infarction, and septicemia. 
2) Congestive heart failure requiring pharmacologic treatment.  
3) Known hypersensitivity to metformin hydrochloride.  
4) Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or 
without coma. Diabetic ketoacidosis should be treated with insulin. 
Metformin should be temporarily discontinued in patients undergoing 
radiologic studies involving intravascular administration of iodinated contrast 
materials, because use of such products may result in acute alteration of renal 
function. 
Drug Interactions 
Glyburide 
The influence of glyburide on metformin pharmacokinetics was assessed in a single-
dose interaction study in healthy subjects. Co-administration of a single dose of 500 
mg metformin and 5 mg glyburide did not result in any changes in metformin 
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pharmacokinetics as AUC, Cmax as well as Tmax were unchanged. Changes in 
Pharmacodynamic were not evaluated in this study. 
Furosemide 
A single-dose, metformin-furosemide drug interaction study in healthy subjects 
demonstrated that pharmacokinetic parameters of both compounds were affected by 
co-administration. Furosemide increased the metformin plasma and blood Cmax by 
22% and blood AUC by 15%, without any significant change in metformin renal 
clearance. When administered with metformin, the Cmax and AUC of furosemide 
were 31 % and 12% smaller, respectively, than when administered alone, and the 
terminal half-life was decreased by 32%, without any significant change in furosemide 
renal clearance. No information is available about the interaction of metformin 
and furosemide when co-administered chronically. 
Nifedipine 
A single-dose, metformin-nifedipine drug interaction study in normal healthy 
volunteers demonstrated that co-administration of nifedipine increased plasma 
metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount 
excreted in the urine. Tmax  and half-life were unaffected. Nifedipineappears to enhance 
the absorption of metformin. Metformin had minimal effects on nifedipine. 
Cationic drugs 
Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, 
ranitidine, triamterene, trimethoprim, or Vancomycin) that are eliminated by renal 
tubular secretion theoretically have the potential for interaction with 
metformin by competing for common renal tubular transport  systems. Such 
interaction between metformin and oral cimetidine has been observed in 
normal healthy volunteers in both single- and multiple-dose, metformin-
cimetidine drug interaction studies, with a 60% increase in peak metformin 
plasma and whole blood concentrations and a 40% increase in plasma and whole 
blood metformin AUC. There was no change in elimination half-life in the single-
dose study. Metformin had no effect on cimetidine pharmacokinetics. 
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Although such interactions remain theoretical (except for cimetidine), careful 
patient monitoring and dose adjustment of metformin and/or the interfering 
drug is recommended in patients who are taking cationic medications that are 
excreted via the proximal renal tubular secretory system. 
Others 
Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic 
control. These drugs include the thiazides and other diuretics, 
corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, 
phenytoin, nicotinic acid, sympathomimetics, cA1cium channel blocking drugs, 
and isoniazid. When such drugs are administered to a patient receiving metformin, 
the patient should be closely observed for loss of blood glucose control. When 
such drugs are withdrawn from a patient receiving metformin, the patient 
should be observed closely for hypoglycemia. In healthy volunteers, 
the pharmacokinetics of metformin and propranolol, and metformin and 
ibuprofen were not affected when co-administered in single-dose interaction 
studies. Metformin is negligibly bound to plasma proteins and is, therefore, less 
likely to interact with highly protein-bound drugs such as salicylates, 
sulfonamides, chloramphenicol, and probenecid, as compared to the 
sulfonylurea, which are extensive. 
Adverse effects 
The most common adverse effect of motorman is gastrointestinal upset, 
including diarrhea, cramps, nausea, vomiting and increased flatulence; 
motormanis more commonly associated with gastrointestinal side effects than 
most other anti-diabetic drugs. The most serious potential side effect of 
motorman use is lactic acidosis; this complication is very rare, and the vast 
majority of these cases seems to be related to co morbid conditions such as 
impaired liver or kidney function, rather than to the motorman itself. 
Motorman has also been reported to decrease the blood levels of thyroid stimulating 
hormones in patients with hypothyroidism and, in men, luteinizing hormone and 
testosterone. The clinical significance of these changes is still unknown. 
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2. Glimepiride40 
Class : Antidiabetic agent 
General Description 
Glimepiride is used for the treatment of diabetes mellitus type 2. 
Mechanism of action 
The primary mechanism of action of AMARYL
®
 (glimepiride) in lowering blood 
glucose appears to be dependent on stimulating the release of insulin from functioning 
pancreatic beta cells. In addition, extra-pancreatic effects may also play a role in the 
activity of glimepiride. This is supported by both preclinical and clinical studies 
demonstrating that glimepiride administration can lead to increased sensitivity of 
peripheral tissues to insulin. However, the mechanism by which glimepiride lowers 
blood glucose during long-term administration has not been clearly established.   
Chemical data  
Proper name  :   Glimepiride   
Chemical name :1-[{p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-
1carboxamido)ethyl]phenyl}sulfonyl]-3-(trans-4methylcyclohexyl)urea   
Molecular formula and molecular mass: C24H34N4O5S  490.62 
Physicochemical properties: Glimepiride is a white to yellowish-white, crystalline, 
odorless to practically odorless powder.   
Glimepiride is practically insoluble in water.  
pKa values:  6.2 ± 0.1 at 37°C 
 Melting point:  207°C 
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Chemical structure 
 
 
Pharmacokinetics 
Absorption:  
After oral administration, glimepiride is completely (100%) absorbed from the GI 
tract. Studies with single oral doses in normal subjects and with multiple oral doses in 
patients with type 2 diabetes have shown significant absorption of glimepiride within 
1 hour after administration and peak drug levels (Cmax) at 2 to 3 hours. 
Distribution:  
After intravenous dosing in normal subjects, the volume of distribution (Vd) was 8.8 L 
(113 ml/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was 
greater than 99.5%. 
Metabolism: 
Glimepiride is completely metabolized by oxidative biotransformation after either IV 
or oral administration. The major metabolites are the cyclohexylhydroxy methyl 
derivative (M1) and the carboxyl derivative (M2). 
Excretion: 
When 14C-glimepiride was given as a single dose orally, approximately 60% of the 
total radioactivity was recovered in the urine in 7 days and metabolites M1 
(predominant) and M2 accounted for 80-90% of that recovered in the urine. 
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Approximately 40% of the total radioactivity was recovered in feces and metabolites 
M1 and M2 (predominant) accounted for about 70. 
Special Populations and Conditions   
Pediatrics: No studies were performed in pediatric patients.   
Geriatrics: There were no significant differences in glimepiride pharmacokinetics 
between the two age groups. The mean AUC at steady state for the older patients was 
about 13% lower than that for the younger patients. 
Gender: There were no differences between males and females in the 
pharmacokinetics of glimepiride when adjusting for differences in body weight.   
Race: No pharmacokinetic studies to assess the effects of race have been performed. 
Hepatic Insufficiency: No studies were performed in patients with hepatic 
insufficiency.   
Pregnant Women: There are no adequate and well-controlled studies in pregnant 
women. 
Renal Insufficiency: Mean urinary excretion of metabolites M1 plus M2 as percent 
of dose, however, decreased (44.4%, 21.9%, and 9.3%). 
Indication and usage 
 Glimepiride is indicated as an adjunct to proper dietary management, exercise and 
weight reduction to lower the blood glucose in patients with type 2 diabetes whose 
hyperglycemia cannot be controlled by diet and exercise alone.  It may be used in 
combination with metformin when diet and exercise.  It is also indicated for use in 
combination with insulin to lower blood glucose in patients with type 2 diabetes 
whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an 
oral hypoglycemic agent alone.  
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Dosage and Administration 
Usual Starting Dose 
The usual starting dose of glimepiride as initial therapy is 1 mg once daily, 
administered with breakfast or the first main meal. 
Metformin Combination Therapy 
Combination therapy with glimepiride  and metformin may be used in patients who 
do not respond adequately to the maximal dose of glimepiride or in secondary failure 
patients. 
Insulin Combination Therapy 
Combination therapy with glimepiride and insulin may be used in secondary failure 
patients. The recommended glimepiride dose is 8 mg once daily administered with the 
first main meal. After starting with low-dose insulin, upward adjustments of insulin 
can be done approximately weekly as guided by frequent measurements of fasting 
blood glucose. 
Storage and Stability   
Store between 15°C and 30°C. Dispense in well-closed container. 
Drug Interactions 
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, 
including anabolic steroids and male sex hormones, ACE inhibitors, insulin and other 
oral antidiabetics, nonsteroidal anti-inflammatory drugs and other drugs that are 
highly protein bound, such as azapropazone, sulfonamides (e.g. sulphaphenazole), 
chloramphenicol, clarithromycin, coumarins, cyclophosphamide, disopyramide, 
fenyramidol, fenfluramine, fibrates, fluconazole, fluoxetine, guanethidine, ifosfamide, 
miconazole, monoamine oxidase inhibitors, oxyphenbutazone, 
paraaminosalicylicacid, pentoxifylline (high dose parenteral), phenylbutazone, 
probenecid, propranolol, quinolones, salicylates, sulfonamide antibiotics, 
sulfinpyrazone, and tetracycline.   
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Adverse reactions 
Body as a whole: abdominal pain, laboratory test abnormal, and pain in extremity   
Cardiovascular: palpitation and vasodilation   
Digestive: diarrhea, increased appetite, dyspepsia, anorexia, and gastrointestinal pain   
Metabolic and Nutritional Disorders: hypoglycemic reaction and hyperglycemia   
Nervous system: tremor, insomnia, sweating increased, nervousness, dry mouth, hot 
flashes, and paresthesia   
Skin and appendages: pruritus and urticaria 
Special Senses: blurred vision   
Urogenital System: increased urinary frequency and nocturia 
Warning 
Over a period of time, patients may become progressively less responsive to therapy 
with oral hypoglycemic agents because of deterioration of their diabetic state. 
 
3. Gliclazide40 
Class: Antidiabetic agent 
General Description : Gliclazide is used for the treatment of  type 2  diabetes 
mellitus . 
Mechanism of action 
Gliclazide is a hypoglycemic agent of the sulfonylurea group.  The hypoglycemic 
action of gliclazide is related to an improvement in insulin secretion from the 
functioning beta cells of the pancreas.  It potentiates the insulin release, improves the 
dynamics of insulin.  Increase in postprandial insulin and C-peptide secretion persists 
after two years of treatment.  Gliclazide has extra-pancreatic actions.  These metabolic 
actions are accompanied by hemovascular effects.  However, the mechanism of action 
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regarding these effects is still poorly understood.  The clinical significance of these 
effects has not been established. 
Chemical Data 
Proper name :  gliclazide 
Chemical name :1-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-
[(4methylphenyl)sulphonyl]urea  (European Pharmacopoeia)   
Molecular formula: C15H21N3O3S   
Molecular mass : 323.4   
Physicochemical properties:  
Appearance:  white or almost white powder.  
Solubility: practically insoluble in water  freely soluble in methylene chloride  
sparingly soluble in acetone  slightly soluble in ethanol 96%. Acid function pKa:  5.6 
Overall distribution coefficient of gliclazide between water and octanol at pH 7.4 
(Log D pH 7.4) is 0.4 
Melting point: Approximately 168°C  
 
Chemical structure 
 
Pharmacokinetics 
Absorption: Gliclazide is slowly and completely absorbed from the gastro-intestinal 
tract (mean absolute bioavailability of 97%). After administration, plasma 
concentrations rise gradually and the maximum concentration is usually reached after 
about 6 hours, with a plateau maintained for another 4 to 6 hours. 
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Distribution 
A single daily dose maintains effective gliclazide plasma concentrations over 24 
hours. 
Metabolism 
 Although more than 90% of unchanged gliclazide is found in plasma following oral 
administration, this is extensively metabolized with little of the unchanged compound 
(<1%) found in urine.  Six principal metabolites have been identified in urine, 
essentially oxidized and hydroxylated derivatives, and two glucurono conjugates.  No 
active metabolites have been detected in plasma. 
Excretion 
Gliclazide metabolites and conjugates are primarily (60-70%) eliminated via the 
urine, with about 10 to 20% elimination via feces. The mean elimination half life is 16 
h (range 12-20 h). 
Special Populations and Conditions   
Pediatrics: Safety and effectiveness of gliclazide in children have not been 
established,therefore not recommended for use in children and adolescents.   
Geriatrics:  No clinically significant modifications in the pharmacokinetic 
parameters have been observed in elderly patients.    
Gender:  No significant relationship was found between any of the pharmacokinetic 
parameters and the covariates gender, body weight and creatinine clearance.   
Dosage and Administration   
The daily dose of gliclazide may vary from 30 to 120 mg once daily (i.e., one half 
tablet to 2 tablets of gliclazide 60 mg, or 1 to 4 tablets of gliclazide  30 mg).   
A single daily dose provides effective blood glucose control.  The single daily dose 
may be between 30 mg and 90 mg, or even 120 mg.  The daily dose should not exceed 
120 mg.   
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Dose adjustment should be carried out in steps of 30 mg, according to the blood 
glucose response.  Each step should last for at least two weeks. 
Contraindication 
The concomitant use of miconazole and gliclazide is contraindicated. 
Pregnant Women:  Gliclazide is contraindicated in pregnancy.  It is recommended that 
insulin be used during pregnancy in diabetic women. 
Drug Interaction 
As a result of drug interaction, hypoglycemia may be potentiated when a sulfonylurea 
is used concurrently with agents such as: long-acting sulfonamides, tuberculostatics, 
NSAIDs, fibrates, monoamine oxidase inhibitors, salicylates, probenecid, beta-
blockers, azole antifungal agents (oral and parenteral preparations), H2 receptor 
antagonists, angiotensin converting enzyme inhibitors and clarithromycin. In addition, 
while not approved for use with other antidiabetic agents, hypoglycaemia is 
potentiated when gliclazide is used in combination with other antidiabetic agents.       
Barbiturates should be used with caution in patients receiving an oral hypoglycemic 
agent since they may reduce the hypoglycemic effect.   
Sulfonylureas may potentiate the action of anticoagulants.  
Adverse Reactions 
The most frequent adverse drug reactions are hypoglycaemia and gastrointestinal 
disturbances (including abdominal pain, nausea, vomiting, dyspepsia, diarrhea, 
constipation).   
Serious adverse drug reactions during clinical trials were malaise, acute renal failure, 
and thrombophlebitis 
Storage and Stability 
Store at room temperature (15°C-30°C). Keep out of reach of children and pets. 
Unused medication should not be disposed of down the drain or in household garbage. 
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Warnings and Precautions 
Periodic assessment of cardiovascular, ophthalmic, renal and hepatic status is 
advisable.   Since the effects of oral hypoglycemic agents on the vascular changes and 
other long-term sequelae of diabetes mellitus are not fully known, patients receiving 
such drugs must be closely observed for both short- and long-term complications. 
 
 
4.Canagliflozin
41,42,43 
Class: SGLT2 inhibitors 
General Description: It is an oral hypoglycemic drug used in the treatment of type2 
diabetes mellitus. 
Mechanism of Action 
Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is 
responsible for the majority of the reabsorption of filtered glucose from the tubular 
lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin 
reduces reabsorption of filtered glucose and lowers the renal threshold for glucose 
(RTG), and thereby increases urinary glucose excretion (UGE). 
Chemical Data  
Chemical Formula: C24H25FO5S•1/2 H2O 
Chemicalname:(1S)-1,5-anhydro-1-[3-[[5(4-fluorophenyl)-2-thienyl]methyl]-4-
methylphenyl]-D-glucitol hemihydrate 
molecular weight: 453.53 
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Chemical Structure 
 
Pharmacokinetics 
The pharmacokinetics of canagliflozin is similar in healthy subjects and patients with 
type 2 diabetes. 
Absorption 
 The mean absolute oral bioavailability of canagliflozin is approximately 65%. 
Plasma Cmax and AUC of canagliflozin increased in a dose-proportional manner 
from 50 mg to 300 mg. The apparent terminal half-life (t1/2) was 10.6 hours and 
13.1 hours for the 100 mg and 300 mg doses, respectively. Steady-state was reached 
after 4 to 5 days of once-daily dosing with canagliflozin 100 mg to 300 mg. 
Distribution 
The mean steady-state volume of distribution of canagliflozin following a single 
intravenous infusion in healthy subjects was 83.5 L, suggesting extensive tissue 
distribution. Canagliflozin is extensively bound to proteins in plasma (99%),  mainly 
to albumin. 
Metabolism 
O-glucuronidation is the major metabolic elimination pathway for canagliflozin, 
which is mainly glucuronidated by UGT1A9 and UGT2B4 to two inactive O-
glucuronide metabolites. 
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Excretion 
Mean systemic clearance of canagliflozin was approximately 192 mL/min in healthy 
subjects following intravenous administration. 
Specific Populations  
Renal Impairment 
Renal impairment did not affect the Cmaxof canagliflozin. The pharmacodynamic 
response to canagliflozin declines with increasing severity of renal impairment. 
Canagliflozin was negligibly removed by hemodialysis. 
Hepatic Impairment 
Relative to subjects with normal hepatic function, the geometric mean ratios for Cmax 
and AUC∞ of canagliflozin were 107% and 110%, respectively, in subjects with 
Child-Pugh class A (mild hepatic impairment) and 96% and 111%, respectively, in 
subjects with Child-Pugh class B (moderate hepatic impairment) following 
administration of a single 300 mg dose of canagliflozin. 
Combination Therapy 
Add-on Combination Therapy with Metformin 
Canagliflozin 100 mg and 300 mg once daily also resulted in a greater proportion of 
patients achieving an HbA1c less than 7%, in significant reduction in fasting plasma 
glucose (FPG), in improved postprandial glucose (PPG), and in percent body weight 
reduction compared to placebo when added to metformin. 
Adverse Reactions  
The following important adverse reactions are: 
 • Hypotension  
 • Ketoacidosis  
 • Acute Kidney Injury and Impairment in Renal Function  
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 • Hyperkalemia  
 • Urosepsis and Pyelonephritis  
 • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues 
 • Genital Mycotic Infections  
 • Hypersensitivity Reactions  
 • Bone Fracture 
 • Increases in Low-Density Lipoprotein (LDL-C) 
Dosage and Administration  
• The recommended starting dose is 100 mg once daily, taken before the first meal of 
the day. 
• Dose can be increased to 300  mg once daily in patients tolerating 
canagliflozin100 mg once daily who have an eGFR of 60 mL/min/1.73 m
2
 or greater 
and require additional glycemic control.  
 • Assess renal function before initiating and periodically thereafter.  
 • Limit the dose of canagliflozin to 100 mg once daily in patients who have an eGFR 
of 45 to less than 60 mL/min/1.73 m
2
 
 • Initiation or use of canagliflozin is not recommended if eGFR is below 45 
mL/min/1.73 m
2
 
Dosage Forms and Strengths  
100 mg, 300 mg  
Storage and Handling  
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). 
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Warnings and Precautions 
Hypotension: Before initiating canagliflozin assess volume status and correct 
hypovolemia in patients with renal impairment, the elderly, in patients with low 
systolic blood pressure, or if on diuretics, ACEi, or ARB. Monitor for signs and 
symptoms during therapy  
Ketoacidosis: Assess patients who present with signs and symptoms of metabolic 
acidosis for ketoacidosis, regardless of blood glucose level.  
Acute kidney injury and impairment in renal function: Consider temporarily 
discontinuing in settings of reduced oral intake or fluid losses. If acute kidney injury 
occurs, discontinue and promptly treat. Monitor renal function during therapy.  
Hyperkalemia: Monitor potassium levels in patients with impaired renal function and 
in patients predisposed to hyperkalemia  
Urosepsis and Pyelonephritis: Evaluate patients for signs and symptoms of urinary 
tract infections and treat promptly 
Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce 
the risk of hypoglycemia when used in combination with canagliflozin. 
Genital mycotic infections: Monitor and treat if indicated.  
Hypersensitivity reactions: Discontinue canagliflozin and monitor until signs and 
symptoms resolve.  
Bone fracture: Consider factors that contribute to fracture risk before initiating 
canagliflozin 
Increased LDL-C: Monitor LDL-C and treat if appropriate.  
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5. Dapagliflozin
46
 
Class: SGLT2 inhibitors 
General Description: It is an oral hypoglycemic drug used in the treatment of type2 
diabetes mellitus. 
Mechanism of Action 
Dapagliflozin is a reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2) 
that improves glycemic control in patients with type 2 diabetes mellitus by reducing 
renal glucose reabsorption leading to urinary excretion of excess glucose (glucuresis). 
SGLT2 is selectively expressed in the kidney. SGLT2 is the predominant transporter 
responsible for reabsorption of glucose from the glomerular filtrate back into the 
circulation. Dapagliflozin improves both fasting and post-prandial plasma glucose 
levels by reducing renal glucose reabsorption leading to urinary excretion of excess 
glucose. The amount of glucose removed by the kidney through this mechanism is 
dependent upon the blood glucose concentration and GFR. Dapagliflozin does not 
impair normal endogenous glucose production in response to hypoglycemia.  
Dapagliflozin acts independently of insulin secretion and insulin action. Urinary 
glucose excretion (glucuresis) induced by dapagliflozin is associated with caloric loss 
and reduction in weight. Inhibition of glucose and sodium co-transport by 
dapagliflozin is also associated with mild diuresis and transient natriuresis. 
Dapagliflozin does not inhibit other glucose transporters important for glucose 
transport into peripheral tissues and is greater than 1400 times more selective for 
SGLT2 vs. SGLT1, the major transporter in the gut responsible for glucose 
absorption. 
Chemical Data 
Common Name: Dapagliflozinpropanediol monohydrate 
Chemical Name: D-glucitol,1,5-anhydro-1-C-[4-chloro-3-
[(4ethoxyphenyl)methyl]phenyl]-, (1S)-,compd. with (2S)-1,2-propanediol, hydrate 
(1:1:1)  
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Molecular Formula: C21H25ClO6 •C3H8O2 •H2O  
Molecular mass: 502.98; 408.87  
Physicochemical Properties: Dapagliflozin propanediol is a white to off-white non-
hygroscopic crystalline powder. It is slightly soluble in water, soluble in acetonitrile 
and freely soluble in acetone, ethanol, isopropanol, methanol and tetrahydrofuran. 
Chemical Structure 
 
Pharmacokinetics 
Absorption:  Dapagliflozin was rapidly and well absorbed after oral administration 
and can be administered with or without food. Geometric mean steady-state 
dapagliflozin Cmax and AUCτ values following once daily 10 mg doses of 
dapagliflozin were 158 ng/mL and 628 ng/mL, respectively. Maximum dapagliflozin 
plasma concentrations (Cmax) were usually attained within 2 hours after 
administration in the fasted state. 
Distribution:  Dapagliflozin is approximately 91% protein bound. Protein binding 
was not altered in various disease states (eg, renal or hepatic impairment).  
Metabolism: The mean plasma terminal half-life (t1/2) for dapagliflozin was 12.9 
hours. 
Excretion:  Dapagliflozin and related metabolites are primarily eliminated via urinary 
excretion, of which less than 2% is unchanged dapagliflozin. 
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Indications and Clinical Use 
Monotherapy: Dapagliflozin is indicated as an adjunct to diet and exercise to 
improve glycemic control in patients with type 2 diabetes mellitus for whom 
metformin is inappropriate due to contraindications or intolerance. 
Add-on combination: It is indicated in patients with type 2 diabetes mellitus to 
improve glycemic control in combination with: • metformin, • a sulfonylurea, or • 
insulin (alone or with metformin) when the existing therapy, along with diet and 
exercise, does not provide adequate glycemic control. 
Special Populations and Conditions 
No dosage adjustments based on pharmacokinetic analyses are recommended for mild 
renal impairment, mild, moderate and severe hepatic impairment, age, gender, race 
and body weight.  
Pediatrics (< 18 years of age):  Pharmacokinetics in the pediatric and adolescent 
population have not been studied. 
Drug Interactions 
Dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered 
medications that are P-gp, OCT2, OAT1, or OAT3 substrates. 
Drug-Drug Interactions Effect of other drugs on dapagliflozin 
In studies conducted in healthy subjects, the pharmacokinetics of dapagliflozinare not 
altered by the co-administered drugs. 
Adverse Reactions 
The most commonly reported adverse events during treatment with FORXIGA 5 mg 
or 10 mg (≥5%) were female genital mycotic infections, nasopharyngitis and urinary 
tract infections. 
Contraindications 
Dapagliflozin is contraindicated in:  
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• Patients with a history of hypersensitivity reaction to the active substance or to any 
of the excipients. 
• Patients with moderate to severe renal impairment, defined as an estimated 
glomerular filtration rate (eGFR) <60 mL/min/1.73m
2
, or end-stage renal disease 
[ESRD]. 
Monitoring and Laboratory Tests Renal function: 
 Renal function should be assessed prior to initiation of Dapagliflozin and regularly 
thereafter as it is contraindicated in patients with an eGFR<60 mL/min/1.73 m
2
. 
 Reduced intravascular volume:  Dapagliflozin is not recommended for use in patients 
who are volume depleted.  
LDL-cholesterol:  LDL-C levels should be monitored during treatment with 
dapagliflozin due to dose-dependent increases in LDL-C seen with therapy. 
Special Populations 
Pregnant Women:  Dapagliflozin must not be used in pregnancy. 
Nursing Women:   Dapagliflozin must not be used by a nursing woman. 
Pediatrics (< 18 years of age):  Safety and effectiveness  in pediatric patients have not 
been established, therefore should not be used in this population. 
Geriatrics (≥ 65 years of age): Older patients are more likely to have impaired renal 
function. 
Storage And Stability 
 Store at room temperature (15-30°C). Keep in a safe place out of reach of children. 
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6. Empagliflozin44,45 
Class: SGLT2 inhibitor 
General Description: It is an oral hypoglycemic drug used in the treatment of type2 
diabetes mellitus. 
Mechanism of Action  
Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible 
for reabsorption of glucose from the glomerular filtrate back into the circulation. 
Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces 
renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and 
thereby increases urinary glucose excretion. 
Chemical Data 
Common name:  Empagliflozin 
Chemical name: (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3 
yloxy]benzyl}phenyl)-D-glucitol 
Molecular formula:  C23H27ClO7  
Molecular mass: 450.91 g/mol  
Structural formula : 
 
Physicochemical parameters: 
Empagliflozin is a white to yellowish, not hygroscopic solid powder, very slightly 
soluble in water (0.28 mg/mL ) 
 sparingly soluble in methanol (33.4 mg/mL), 
 slightly soluble in ethanol (8.0 mg/mL) 
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 slightly soluble in acetonitrile (2.6 mg/mL) 
 slightly soluble in 50% methanol in water (6.4 mg/mL) 
 soluble in 50% acetonitrile in water (68 mg/mL) 
 practically insoluble in toluene (<0.001 mg/mL). 
Pharmacokinetics 
Absorption: After oral administration in patients with T2DM, empagliflozin was 
rapidly absorbed with peak plasma concentrations occurring at a median Tmax 1.5 h 
post-dose. Thereafter, plasma concentrations declined in a biphasic manner with a 
rapid distribution phase and a relatively slow terminal elimination phase. 
Distribution: The apparent steady-state volume of distribution was estimated to be 
73.8 L, based on a population pharmacokinetic analysis. Following administration of 
an oral [14C]-empagliflozin solution to healthy subjects, the red blood cell 
partitioning was approximately 36.8% and plasma protein binding was 86.2%, mainly 
to albumin. 
Metabolism: No major metabolites of empagliflozin were detected in human plasma 
and the most abundant metabolites were three glucuronide conjugates (2-O-, 3-O-, 
and 6-O-glucuronide). Systemic exposure of each metabolite was less than 10% of 
total drug-related material. 
Excretion: The apparent terminal elimination half-life of empagliflozin was 
estimated to be 12.4h and apparent oral clearance was 10.6 L/h based on the 
population pharmacokinetic analysis. 
 
Indications and Clinical Use  
 
Monotherapy 
Empagliflozin is indicated for use as an adjunct to diet and exercise to improve 
glycemic control in adult patients with type 2 diabetes mellitus for whom metformin 
is inappropriate due to contraindications or intolerance.  
 
SGLT2 Inhibitors in NIDDM  Page 82 
 
Add-on combination: is indicated in adult patients with type 2 diabetes mellitus to 
improve glycemic control, when metformin used alone does not provide adequate 
glycemic control, in combination with:  
• metformin,  
• metformin and a sulfonylurea,  
• pioglitazone (alone or with metformin),  
• basal or prandial insulin (alone or with metformin),  
when the existing therapy, along with diet and exercise, does not provide adequate 
glycemic control. 
Special Populations and Conditions  
 
Pediatrics (<18 years of age):  
Studies characterizing the pharmacokinetics of empagliflozin in pediatric patients 
have not been performed.  
 
 
Geriatrics (≥65 years of age):  
Age did not have a clinically meaningful impact on the pharmacokinetics of 
empagliflozin based on the population pharmacokinetic analysis. 
 
Body Mass Index: BMI had no clinically relevant effect on the pharmacokinetics of 
empagliflozin based on the population pharmacokinetic analysis. 
 
Gender: Gender had no clinically relevant effect on the pharmacokinetics of 
empagliflozin based on the population pharmacokinetic analysis.  
 
Race: Based on the population pharmacokinetic analysis, AUC was estimated to be 
13.5% higher in Asian patients with a BMI of 25 kg/m
2
 compared to non-Asian 
patients with a BMI of 25 kg/m
2
. These changes are not considered clinically 
meaningful.  
 
Hepatic Insufficiency: In subjects with mild, moderate, and severe hepatic 
impairment according to the Child-Pugh classification, AUC of empagliflozin 
increased approximately by 23%, 47%, and 75% and Cmax by approximately 4%, 
SGLT2 Inhibitors in NIDDM  Page 83 
 
23%, and 48%, respectively, compared to subjects with normal hepatic function. 
Experience in patients with severe hepatic impairment is limited. 
Renal Insufficiency: In patients with mild (eGFR: 60 - <90 mL/min/1.73m2), 
moderate (eGFR: 30 - <60 mL/min/1.73m2), severe (eGFR: <30 mL/min/1.73m2) 
renal impairment and patients with kidney failure/ESRD patients, AUC of 
empagliflozin increased by approximately 18%, 20%, 66%, and 48%, respectively, 
compared to subjects with normal renal function. 
Monitoring and Laboratory Tests  
 
Blood Glucose and HbA1c: Response to empagliflozin treatment should be 
monitored by periodic measurements of blood glucose and HbA1c levels.  
 
Renal Function: Renal function should be assessed prior to initiation of 
empagliflozin and regularly thereafter, with more frequent monitoring in patients 
whose eGFR decreases to <60 mL/min/1.73m
2
. 
 
Reduced Intravascular Volume: Empagliflozin is not recommended for use in 
patients who are volume.Temporary interruption of treatment with JARDIANCE 
should be considered until fluid loss is corrected. 
 
LDL-Cholesterol: LDL-cholesterol levels should be measured at baseline and at 
regular intervals during treatment with empagliflozin due to dose-dependent increases 
in LDL-C seen with therapy. 
Adverse Reactions 
 Genital Mycotic Infections 
 Increased urination 
 Urinary Tract Infections 
 Volume Depletion and hypotension 
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WARNINGS AND PRECAUTIONS  
General  
Empagliflozin is not indicated for use in patients with type 1 diabetes and should not 
be used for the treatment of diabetic ketoacidosis.  
 
Cardiovascular  
Use in Patients at Risk for Volume Depletion, Hypotension and/or Electrolyte 
Imbalancesdue to its mechanism of action, Empagliflozin causes diuresis that may be 
associated with decreases in blood pressure. 
 
Special Populations  
 
Pregnant Women: must not be used in pregnancy.  
Nursing Women: must not be used in nursing women.  
Storage And Stability  
Store at room temperature (15-30°C). 
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6. LITERATURE REVIEW 
Wilding J. P. H et al., in 2013 conducted a randomised double blind placebo –
controlled phase 3 study evaluating the efficacy and safety of canagliflozin as on add-
on to metformin plus sulphonyl urea in patients with N= 469 T2DM patients received 
canagliflozin 100 or 300 mg or placebo once daily during a 26-week core period and a 
26 week extension. Prespecified primary end –point was change in HbA1c at 26 
weeks  and secondary end-points included change in HbA1c at 52 week as well as a 
proportion of patients achieving significant reduction in HbA1c with canagliflozin 
100and 300mg vs placebo at week 26 and the reductions were maintained at week 52. 
Both canagliflozin doses reduced FPG and body weight vs placebo at week 26 and 
week 52. The study concluded that canagliflozin improved glycaemic control, reduced 
body weight, and was generally well tolerated in T2DM  patients on metformin plus 
sulphonyl urea over 52 weeks. 
Rong Qui et al., in 2014 evaluated the efficacy /safety of canagliflozin twice daily 
(BID)compared with placebo in patients with type 2 diabetes mellitus on metformin. 
An 18 week, randomised, double-blind, placebo controlled study with N=279 
received canagliflozin 50 or 150 mg or placebo BID. The pre-specified primary end 
point was change from baseline in HbA1c at week 18 and the pre-specified secondary 
endpoints included proportion of patients reaching HbA1c <7.0%, change in FPG, and 
percent change in bodyweight , changes in systolic blood pressure and fasting plasma 
lipids were also evaluated and AEs were recorded throughout the study and noted that 
both the canagliflozin doses significantly lowered FPG and body weight and reduced 
systolic BP. The study concluded that canagliflozin 50 and 150 mg BID provided 
significant glycemic efficacy and bodyweight reduction and were generally well 
tolerated in patients with T2DM on background metformin. 
Forst T et al., in 2014 evaluated the efficacy and safety of canagliflozin in patients 
with T2DM inadequately controlled with metformin and pioglitazone in a randomised 
double blind, phase 3 study with patients N=342 received 100 or 300 mg during a 26 
week placebo-controlled, core period and a 26 week active controlled extension in 
which placebo treated patients were switched to sitagliptin 100mg. The study revealed 
that canagliflozin 100 and 300 mg significantly lowered HbA1c compared with 
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placebo at week 26 and were maintained at week 52 . The study concluded that 
canagliflozin improved glycaemic control , reduced body weight and systolic BP and 
was generally well tolerated in patients with T2DM on metformin and pioglitazone 
over 52 weeks. 
Lavalle Gonzalez F. J et al., in 2013 aimed to evaluate the efficacy and safety of 
canagliflozinverses placebo and sitagliptin in patients with type 2 diabetes who were 
being treated with background metformin in a randomised, double blind , four arm 
parallel group consisting of N=1,284 with t2dm aged >18 and <80 years who had 
inadequate glycaemic control HbA1c >7.0%and <10.5% on metformin therapy 
received canagliflozin100 mg or 300mg, sitagliptin 100mg, or placebo 
(n=368,367,366,183, respectively) for a 26 week, placebo- and active controlled 
period followed by a 26 week , active controlled period (placebo group switched to 
sitagliptin ). The primary endpoint was change from baseline in HbA1c at week 26 , 
secondary end points included changes in HbA1c (week 52) and FPG, body weight 
and systolic blood pressure (weeks 26 and 52) AEs were recorded throughout the 
study. The study concluded that canagliflozin improved glycaemia and reduced body 
weight vs placebo (week26) and sitagliptin (week 52) and was generally well 
tolerated in patients with T2DM on metformin. 
Michael Nauck A et al., in 2011compared the efficacy, safety, and tolerability of 
dapagliflozin with the sulphonyl urea glipizide in patients with type 2 diabetes 
inadequately controlled with metformin monotherapy. A 52 week, double-blind 
multicentre, active-controlled, non-inferiority trial randomised patients with type 2 
diabetes (baseline mean HbA1c 7.7%), who were receiving metformin monotherapy, 
to add-on dapagliflozin (n=406)or glipizide (n=408) up-titrated over 18 weeks , based 
on glycemic response and tolerability to <10 or <20 mg/day, respectively. The study 
concluded that dapagliflozin reduced weight and produced less hypoglycaemia than 
glipizide in type 2 diabetes inadequately controlled with metformin. 
Ele Ferrannini et al., in 2010 conducted a 24 week parallel group double blind 
placebo controlled phase 3 trial on dapagliflozin monotherapy in type 2 diabetic 
patients with inadequate glycaemic control by diet and exercise with n=485 to receive 
once daily placebo or 2.5 ,5, 10 mg dapagliflozin once daily in the morning (main 
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cohort) or evening (exploratory cohort). The results showed mean A1c changes from 
baseline at week 24 were -0.23% with placebo and -0.58% , -0.77%, -0.89% with 2.5, 
5, 10 mg dapagliflozin respectively. The study concluded that dapagliflozin lowered 
hyperglycaemia in treatment -naïve patients with newly diagnosed type 2 diabetes. 
Alan Sinclair et al., in 2014 evaluated the efficacy and safety of canagliflozin in 
patients with T2DM <65 and > 65yrs of age. A 26 week studies evaluating 
canagliflozin 100 and 300 mg were analyzed. efficacy evaluations included change 
from baseline in glycaemic parameters and systolic blood pressure and percent change 
from baseline in body weight, and percent change from baseline in fasting plasma 
lipids. Both canagliflozin doses reduced HbA1c, FPG , body weight and systolic BP 
relative to placebo in patients <65 and >65 years of age. Changes in lipid parameters 
with canagliflozin were similar in both age subsets. The study concluded that 
canagliflozin improved glycaemic control, body weight, and systolic BP, and was 
generally well tolerated in older patients with T2DM. 
Min Chen et al., in 2016 compared the effectiveness of sodium glucose co-
transporter 2 inhibitors for controlling hyper glycaemia in patients with type 2 
diabetes and a protocol for a systemic review and network meta-analysis were 
performed. The study examined effectiveness and safety of either canagliflozin , 
dapagliflozin, empagliflozin, ipragliflozin, tofogliflozin or luseogliflozin. The study 
was systematically retrieved in MEDLINE, EMBASE and the Cochrane Library, from 
the inception to November 2015. relative effectiveness and harms of the 6 SGLT2 
inhibitors was demonstrated through this systemic review and network meta-analysis. 
Schernthaner G et al., in 2013  evaluated the efficacy and safety of canagliflozin, a 
sodium glucose cotransporter 2 inhibitor, compared with sitagliptin in subjects with 
type 2 diabetes inadequately controlled with metformin plus sulfonylurea for  52-
weeks, subjects using stable metformin plus sulfonylurea (N = 755) received 
canagliflozin 300 mg or sitagliptin 100 mg daily. At 52 weeks, canagliflozin 300 mg 
demonstrated non-inferiority and, in a subsequent assessment, showed superiority to 
sitagliptin 100 mg in reducing A1c (−1.03% [−11.3 mmol/mol] and −0.66% [−7.2 
mmol/mol], respectively. Greater reductions in FPG, body weight, and systolic BP 
were observed with canagliflozin versus sitagliptin (P < 0.001).  
SGLT2 Inhibitors in NIDDM  Page 88 
 
Overall AE rates were similar with canagliflozin (76.7%) and sitagliptin (77.5%); 
incidence of serious AEs and AE-related discontinuations was low for both groups. 
Findings suggested that canagliflozin may be a new therapeutic tool providing better 
improvement in glycemic control and body weight reduction than sitagliptin, but with 
increased genital infections in subjects with type 2 diabetes using metformin plus 
sulfonylurea. 
Cefalu W T et al., in 2013 compared the efficacy and safety of canagliflozin, an 
SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately 
controlled with metformin.Patients aged 18–80 years with type 2 diabetes and 
glycatedhaemoglobin A1c (HbA1c) of 7·0–9·5% on stable metformin were randomly 
assigned and received canagliflozin 100 mg or 300 mg, or glimepiride (up-titrated to 6 
mg or 8 mg per day) orally once daily. The primary endpoint was change in HbA1c 
from baseline to week 52, with a non-inferiority margin of 0·3% for the comparison 
of each canagliflozin dose with glimepiride.1450 of 1452 randomised patients 
received at least one dose of glimepiride (n=482), canagliflozin 100 mg (n=483), or 
canagliflozin 300 mg (n=485). For lowering of HbA1c at 52 weeks, canagliflozin 100 
mg was non-inferior to glimepiride  and canagliflozin 300 mg was superior to 
glimepiride.The study concluded that Canagliflozin provides greater HbA1c reduction 
than does glimepiride, and is well tolerated in patients with type 2 diabetes receiving 
metformin. 
Bode B et al., in 2013 evaluated the efficacy and safety of canagliflozin therapy in 
older subjects (aged 55-80 years) with T2DM inadequately controlled on their current 
regimen of blood glucose-lowering agents. Subjects (N = 716) aged 55 to 80 years 
(mean, 63.6 years) with glycated hemoglobin (HbA1c) levels ≥ 7.0% to ≤ 10.0% were 
randomized and 714  received canagliflozin 100 mg or 300 mg or placebo (1:1:1) 
daily. At week 26, treatment with canagliflozin 100 mg and 300 mg significantly 
reduced HbA1c levels compared with placebo and both canagliflozin doses 
significantly reduced body weight, FPG level, and systolic BP, and increased HDL-C 
level compared with placebo. Canagliflozin improved glycemic control, reduced body 
weight and systolic BP, and was generally well tolerated in older subjects with T2DM 
who were on background therapy with a variety of blood glucose-lowering agents. 
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Devineni D et al., in 2012 observed a randomized, double-blind, placebo-controlled, 
parallel-group, 28-day study conducted at two sites, in 29 subjects with T2DM not 
optimally controlled on insulin and up to one oral antihyperglycaemic agent and the 
subjects were treated with canagliflozin 100 mg QD or 300 mg twice daily (BID) or 
placebo. Safety, tolerability, pharmacokinetic characteristics and pharmacodynamic 
effects of canagliflozin were examined. Glucose malabsorption following a 75-g oral 
glucose challenge was also examined and the results suggested that canagliflozin was 
well tolerated without evidence for glucose malabsorption, had pharmacokinetic 
characteristics consistent with once-daily dosing, and improved glycaemic control. 
Bailey C J et al., in 2010 assessed the efficacy and safety of dapagliflozin in patients 
who have inadequate glycaemic control with metformin.546 adults with type 2 
diabetes who were receiving daily metformin (>/=1500 mg per day) and had 
inadequate glycaemic control were randomly assigned to receive one of three doses of 
dapagliflozin (2.5 mg, n=137; 5 mg, n=137; or 10 mg, n=135) or placebo (n=137) 
orally once daily. The findings suggested that the addition of dapagliflozin to 
metformin provides a new therapeutic option for treatment of type 2 diabetes in 
patients who have inadequate glycaemic control with metformin alone. 
Rosenstock J et al., in 2012 examined the safety and efficacy of dapagliflozin, a 
sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes 
inadequately controlled on pioglitazone.Treatment-naive patients or those receiving 
metformin, sulfonylurea, or thiazolidinedione entered a 10-week pioglitazone dose-
optimization period with only pioglitazone. Patients receiving pioglitazone alone had 
greater weight gain (3 kg) than those receiving dapagliflozin plus pioglitazone (0.7–
1.4 kg) at week 48. Dapagliflozin plus pioglitazone groups had less edema (2.1–4.3%) 
compared with placebo plus pioglitazone (6.5%); and congestive heart failure and 
fractures were rare. The results concluded that in patients with type 2 diabetes 
inadequately controlled on pioglitazone, the addition of dapagliflozin further reduced 
HbA1c levels and mitigated the pioglitazone-related weight gain without increasing 
hypoglycemia risk. 
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Hermansen K et al., in 2007 assessed the efficacy and safety of a 24-week treatment 
with sitagliptin, a highly selective once-daily oral dipeptidyl peptidase-4 (DPP-4) 
inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control 
[glycosylated haemoglobin (HbA1c) >or=7.5% and <or=10.5%] while on glimepiride 
alone or in combination with metformin. Sitagliptin reduced HbA1c by 0.89% relative 
to placebo, compared with a reduction of 0.57% in the subset of patients on 
glimepiride alone. The addition of sitagliptin reduced FPG by 20.1 mg/dl (p < 0.001) 
and increased homeostasis model assessment-beta, a marker of beta-cell function. The 
results suggested that Sitagliptin 100 mg once daily significantly improved glycaemic 
control and beta-cell function in patients with type 2 diabetes who had inadequate 
glycaemic control with glimepiride or glimepiride plus metformin therapy. 
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7. NEED FOR THE PRESENT STUDY 
 
Diabetes is fast gaining the status of a potential endemic in India with more than 62 
million diabetic individuals currently diagnosed with the disease. India currently faces 
an uncertain future in relation to the potential burden that diabetes may impose upon 
our country.  
The level of morbidity and mortality due to diabetes and its potential complications 
are enormous, and pose significant healthcare burdens on both families and society. 
Worryingly, diabetes is now being shown to be associated with a spectrum of 
complications and to be occurring at a relatively younger age within the country. In 
India, the steady migration of people from rural to urban areas, the economic boom, 
and corresponding change in life-style are all affecting the level of diabetes. 
There are a number of challenges that plague diabetes care in India. Yet despite the 
increase in diabetes there remains a paucity of studies investigating the precise status 
of the disease because of the geographical, socio-economic, and ethnic nature of such 
a large and diverse country. Given the disease is now highly visible across all sections 
of society within India, there is now the demand for urgent research and intervention - 
at regional level - to try to mitigate the potentially catastrophic increase in diabetes 
that is predicted for the upcoming years. 
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 8.  AIM AND OBJECTIVE 
AIM 
To study the effectiveness of Sodium-Glucose Transport 2 Inhibitors (SGLT2 
inhibitors) in patients with type 2 diabetes mellitus on the background treatment with 
metformin and a sulphonyl urea 
 
OBJECTIVES 
To assess the glycaemic control by observing: 
• Fasting blood sugar 
• Post-prandial blood sugar 
• Glycosylated haemoglobin (HbA1c) 
• Reduction in body weight 
 
 
 
 
 
 
 
 
SGLT2 Inhibitors in NIDDM  Page 93 
 
9. PLAN OF THE WORK 
 
The Entire study was carried out for a period of nine months from November 2015 
through July 2016. The proposal has been designed as shown below: 
 
NOVEMBER – DECEMBER 2015 
 Obtaining consent from the hospital authorities 
 Survey of Literature  
 Preparation of study design of data entry format (Proforma) 
 Approval from institutional ethics committee (IEC) 
 
JANUARY – JUNE 2016 
 Selection of Patients according to Inclusion-exclusion criteria 
 Obtaining consent from patients 
 Collection of Patient details 
 Collection of Lab and other investigation reports 
 
JULY – AUGUST 2016 
 Compilation 
 Statistical Analysis 
 Submission of Report 
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10. METHODOLOGY 
SITE OF STUDY  
The study was carried out in Trichy Diabetes Speciality Centre (P) Ltd., located in 
Tiruchirappalli, from November 2015 to July 2016. The hospital is unique and well 
known for its services to people who come from all over the district and various parts 
of the state.  
DEPARTMENTS SELECTED FOR THE STUDY  
Patients selected for the study were both in-patients and out-patients 
CONSENT FROM HOSPITAL AUTHORITIES 
It is customary that every project work carried out in the hospital by the Department 
of Pharmacy Practice is informed to all physicians, surgeons, and other health care 
professionals of the hospital after approval. So a protocol of the study, which included 
the objectives, methodology, etc., was submitted to the chairman of the hospital who 
is also the Chairperson of the IEC. 
The scholar was permitted to utilize the hospital facilities to make a follow up of 
prescriptions, in the selected departments. All the health care professionals were well 
informed through official circulars and patients were selected as per selection criteria 
and their consents were obtained after completely explaining to them about the study.  
STUDY DESIGN 
DESIGN OF DATA ENTRY FORMAT: ( PROFORMA ) 
A separate data entry format (Proforma ) for incorporating patient details was 
designed. 
PROFORMA –I 
Patient informed consent form 
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PROFORMA –II 
Patient details such as Name, ID No, Age, Gender , General information like height, 
weight, BMI, general examination details, provisional diagnosis, diabetic and 
hypertensive history, social history, family history of diabetes. 
PROFORMA –III 
Investigation chart – it includes values of diabetic profile study, lipid profile study, 
and biochemistry. 
PROFORMA –IV 
Medication chart 
PATIENT SELECTION CRITERIA 
INCLUSION CRITERIA 
 Type -2 Diabetes  mellitus 
 Insulin unexposed patients 
 Both genders 
 Age above 18 yrs and below 80 years 
EXCLUSION CRITERIA 
 Pancreatitis 
 Pregnancy 
 Breast feeding 
 Renal insufficiency 
 Hepatic insufficiency 
 Malignancy 
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STUDY GROUP 
S.NO STUDY GROUP STUDY DRUGS 
1. Group  A 
(n = 55) 
Metformin & a Sulphonyl urea* 
2. Group B 
(n = 50) 
Metformin+ a Sulphonyl urea* +SGLT2-I** 
 
* Sulphonylurea used included either Gliclazide or Glimepiride 
**SGLT2-I used included either Canagliflozin or Dapagliflozin or Empagliflozin.  
 
STATISTICAL ANALYSIS 
The collected data was analysed by using suitable statistical methods such as one –
way ANOVA , Column statistics etc., using the statistical software “Graph pad – 
prism 5 for windows version 5.01” 
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11.     RESULTS AND DISSCUSSION 
 
This project is designed to study the efficiency of SGLT2 inhibitors in NIDDM 
patients on the backdrop use of metformin and a sulphonyl urea. This study included 
105 type 2 diabetes patients, based on inclusion and exclusion criteria after letting out 
the drop outs numbering 19. 
From the selected 105 patients, 55 patients were treated with Metformin and a 
Sulphonyl Urea (Gliclazide / Glimepiride) combination that were termed Group A 
and remaining 50 patients were treated with Metformin + a Sulphonyl urea + a 
SGLT2- I (Canagliflozin 100mg or Dapagliflozin 10mg or Empagliflozin 10mg) 
combination that were termed Group B.  
In this study the initial readings were considered as base values, after which each 
month values were taken for FPG (Fasting plasma glucose), PP (Post prandial plasma 
glucose), Body weight in kg  etc., and for HbA1c (Glycosylated Haemoglobin) in the 
gap of 3 months once , values were taken. 
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Categorization of Patients in Group A (n=55) according to Gender: 
Out of selected 55 patients, 26 patients (47%) were males, and the remaining 29 
patients (53 %) were females. (Table 10 & Figure 5 ) 
Table 10 
Gender wise Categorization of Group A (Met+Su)  
n=55 
 
Fig. 5 
 
 
 
47% 
53% 
Categorization of Group A (N=55) 
according to Gender 
MALE
FEMALE
Gender No. of patients Percentage (%) 
Male 26 47 
Female 29 53 
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Categorization of Patients in Group B (n=50) according to Gender: 
Out of the selected 50 patients , 23patients (46%) were males, and the remaining 27 
patients (54 %) were females. (Table 11 & Figure 6) 
Table 11 
Gender wise Categorization of Group B (Met+Su+SGLT2-I)  
n=50  
Gender No. of patients Percentage (%) 
Male 23 46 
Female 27 54 
 
Fig. 6 
 
 
 
The demographic data point towards least variation in the gender wise distribution of 
the patients included in the study between both the groups. 
 
23 
27 
Categorization of Group B (n=50)according to 
Gender  
MALE
FEMALE
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Categorization of Patients in Group A (n=55) according to Age : 
Out of the selected 55 patients,  2 patients (4%) were in the age group of 21-30 years, 
9 patients (16%) were in the age group of 31-40 years, 14 patients (25%) were in the 
age group of 41-50 years, 13 patients (24%) were in the age group of 51-60 years, 11 
patients (20%) were in the age group of 61-70 years, 6 patients (11%) were in the age 
group of 71-80 years . (Table 12 & Figure 7) 
Table 12 
Age wise Categorization of Group A (Met+Su)  
n=55  
Age in years No. of patients Percentage (%) 
21-30 2 4 
31-40 9 16 
41-50 14 25 
51-60 13 24 
61-70 11 20 
71-80 6 11 
 
Fig. 7 
 
4% 
16% 
25% 
24% 
20% 
11% 
Categorization of Group A (N=55) 
according To Age in Years 
21-30
31-40
41-50
51-60
61-70
71-80
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Categorization of Patients in Group B (n=50) according to Age: 
Out of the selected 50 patients, 1 patient (2%) was in the age group of 21-30 years, 10 
patients (20%) were in the age group of 31-40 years, 15 patients (30%) were in the 
age group of 41-50 years, 12 patients (24%) were in the age group of 51-60 years,  9 
patients (18%) were in the age group of 61-70 years, 3 patients (6%) were in the age 
group of 71-80 years. (Table 13 & Figure 8) 
Table 13 
Age wise Categorization of Group B (Met+Su+SGLT2-I)  
n=50  
Age in years No. of patients Percentage (%) 
21-30 1 2 
31-40 10 20 
41-50 15 30 
51-60 12 24 
61-70 9 18 
71-80 3 6 
 
Fig.8 
 
1 
10 
15 12 
9 
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Categorization of Patients in Group B 
(N=50)according to Age  in Years 
21-30
31-40
41-50
51-60
61-70
71-80
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Categorization of patients in Group A (n=55) according to their Social Habits: 
Out of the selected 55 patients,36  patient (65%) had none of the following habits, 8  
patients (15%) were tobacco smokers, 5 patients (9%) were tobacco chewers, 4 
patients (7%) were A1coholics, 2  patients (4%) were both A1coholic and tobacco 
smokers.(Table 14 &Figure 9) 
Table 14 
Categorization of Group A (Met+Su) according to Social Habits  
n=55  
Social Habits No. of Patients Percentage (%) 
No habits 36 65 
Tobacco smoking 8 15 
Tobacco chewing 5 9 
A1cohol Intake 4 7 
A1cohol & Tobacco 
smoking 
2 4 
 
Fig. 9 
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Categorization of patients in 
Group A (N=55) according to 
Social Habits  
No habits
Tobacco Smoking
Tobacco Chewing
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Categorization of Patients in Group B (n=50) according to their Social Habits: 
Out of the selected 50 patients, 35 patient (70%) had none of the following habits, 4  
patients (8%) were tobacco smokers, 3 patients ( 6%) were tobacco chewers ,7 
patients (14%) were A1coholics,1 patient (2%) was both A1coholic and tobacco 
smoking.(Table 15 & Figure 10) 
Table 15 
Categorization of Group B (Met+Su+SGLT2-I) according to Social Habits 
n=50 
Social Habits No. of Patients Percentage (%) 
No habits 35 70 
Tobacco smoking 4 8 
Tobacco chewing 3 6 
A1cohol Intake 7 14 
A1cohol & Tobacco 
smoking 
1 2 
Fig. 10 
 
The observed data indicates that 65 – 70% of T2DM patients have no particular social 
habits. 
35 
4 
3 
7 1 
Categorization of Patients in Group B 
According to Social Habits 
NO HABITS
TOBACCO SMOKING
TOBACCO CHEWING
ALCOHOL
ALCOHOL & SMOKING
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Categorization of patients in Group A (n=55) according to Familial history of 
DM: 
Out of the 55 selected patients, 15 patients (27%) had no familial history of diabetes,            
40 patients (73%) had familial history of diabetes of either type 1 or 2. (Table16 & 
Figure11) 
Table 16 
Categorization of Group A (Met+Su) according to Familial History 
n=55 
Familial history No. of patients Percentage (%) 
Non-diabetic family 15 27 
Diabetic  40 73 
 
Fig. 11 
 
 
27% 
73% 
Categorization of patients in Group A 
(N=55) according to Family History 
Non- Diabetic Family
Diabetic Family
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Categorization of patients in  Group B (n=50) according to Familial history of 
DM: 
Out of  the 50 selected patients, 14 patients (28%) had no familial history of diabetes,           
36 patients (72%) had familial history of diabetes. (Table 17 & Figure 12) 
Table 17 
Categorization of Group B (Met+Su+SGLT2-I) according to Familial history 
n=50 
Family history No. of patients Percentage (%) 
Non-diabetic family 14 28 
Diabetic  36 72 
 
Fig. 12 
 
 
From the above table and figure it is evident that T2DM patients with family history 
of  diabetes is comparatively more than patients with non-diabetic family history. 
 
14 
36 
Categorization of patients in Group B 
(N=50) according to Family History 
Non-Diabetic Family
Diabetic Family
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Categorization of patients in  Group A (n=55) according to their Food Habits: 
Out of the 55 selected patients, 31 patients (56%) are vegetarians, 24 patients (44%) 
are having mixed diet. (Table 18 & Figure 13) 
 
Table 18 
Categorization of Group A (Met+Su) according to Food Habits 
n=55 
Food Habit No. of patients Percentage (%) 
Vegetarian diet 31 56 
Mixed diet 24 44 
 
Fig. 13 
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Categorization of patients in Group A 
(N=55) according to Food Habits 
Vegetarian Diet
Mixed Diet
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Categorization of patients in  Group B (n=50) according to their Food Habits: 
Out of the 50 selected patients, 18 patients (36%) are vegetarian, 32 patients (64%) 
are having mixed diet. (Table 19 & Figure 14) 
 
Table 19 
Categorization of Group B (Met+Su+SGLT2-I) according to Food Habits 
n=50 
Food Habits No. of patients Percentage(%) 
Vegetarian diet 18 36 
Mixed diet 32 64 
 
 
 
Fig. 14 
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Categorization of patients in  Group A (n=55) according to BMI:  
Out of the 55 selected patients, 12 patients (22%) were of normal weight, 26 patients 
(47%) were overweight, 8 patients (15%) were in the obese class I criteria, 6 patients 
(11%) were in the obese class II criteria, 3 patients (5%) were in obese class III 
criteria. (Table 20 & Figure 15)  
Table 20 
Categorization of Group A (Met+Su) according to BMI 
n=55 
Body mass index kg/m
2
 No. of patients Percentage (%) 
Under weight 17 - 18.5 0 0 
Normal 18.6 - 25 12 22 
Overweight  25.1 - 30 26 47 
Obese class I  30.1 - 35 8 15 
Obese class II  35.1 - 40 6 11 
Obese class III   > 40 3 5 
 
Fig. 15 
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Normal 18.6-25
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Obese class III > 40
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Categorization of patients in  Group B (n=50) according to BMI: 
Out of the 50 selected patients, 8 patients (16%) were of normal weight, 21 patients 
(42%) were overweight, 11 patients (22%) were in the obese class I criteria, 7 patients 
(14%) were in the obese class II criteria, 3 patients (6%) were in obese class III 
criteria. (Table 21 & Figure 16)  
Table 21 
Categorization of Group B (Met+Su+SGLT2-I) according to BMI 
n=50 
Body mass index kg/m
2
 No. of patients Percentage (%) 
Under weight 17 - 18.5 0 0 
Normal  18.6 - 25 8 16 
Overweight  25.1 - 30 21 42 
Obese class I  30.1 - 35 11 22 
Obese class II  35.1 - 40 7 14 
Obese class III  > 40 3 6 
 
 
Fig. 16 
 
From the above observed data it is very clear that Overweight, Obese Class I tops the 
T2DM in both the groups followed by some normal weight, Obese class II & III 
patients. No under-weight patient is seen with T2DM. 
0 
8 
21 
11 
7 3 
Categorization of patients in Group B 
(N=50) according to BMI in kg/m2 
Under weight 17-18.5
Normal 18.6-25
Over weight 25.1-30
Obese class I 30.1-35
Obese class II 35.1-40
Obese class III > 40
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Categorisation of patients in Group A (n=55) according to Associated diseases: 
Out of the 55 selected patients,44 patients (26%) has hypertention, 32 patients (19%) 
has dyslipidaemia, 18 patients (11%) has cardiovascular disease, 24 patients (14%) 
has peripheral neuropathy, 22 patients (13%) has hypothyroidism, 28 patients (17%) 
has Non A1coholic Fatty Liver Disease (NAFLD). (Table 22 & Figure 17) 
Table 22 
Categorization of Group A (Met+Su) 
with Associated Diseases 
n=55 
Associated Disease No. of patients Percentage (%) 
Hypertension 44 26 
Dyslipidaemia 32 19 
Cardiovascular disease 18 11 
Peripheral neuropathy 24 14 
Hypothyroidism 22 13 
NAFLD 28 17 
 
Fig. 17 
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Categorisation of patients in Group B (n=50) according to Associated diseases: 
Out of the 50 patients,41 patients (22%) has hypertention,38 patients (21%) has 
dyslipidaemia, 23 patients (13%) has cardiovascular disease, 33 patients (18%) has 
peripheral neuropathy, 19 patients(10%) has hypothyroidism, 29 patients (16%) has 
Non A1coholic Fatty Liver Disease.( Table 23 & Figure 18) 
Table 23 
Categorization of Group B (Met+Su+SGLT2-I) with Associated Diseases 
n=50 
Associated Disease No of patients Percentage (%) 
Hypertension 41 22 
Dyslipidaemia 38 21 
Cardiovascular disease 23 13 
Peripheral neuropathy 33 18 
Hypothyroidism 19 10 
NAFLD 29 16 
m 
Fig. 18 
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Table 24 shows the values of Fasting blood sugar for Group A (Metformin & a 
Sulphonyl urea) patients, after every month on taking metformin & a sulphonyl urea 
keeping the first value as base value. 
Table 24 
Effect of Group A on Fasting Blood Sugar 
(n=55) 
PATIENT ID BASE REVIEW 1 REVIEW 2 REVIEW 3 
A1 125 115 121 108 
A2 113 105 111 100 
A3 130 126 106 102 
A4 94 109 99 105 
A5 113 86 83 108 
A6 65 88 72 81 
A7 123 130 152 131 
A8 154 145 142 142 
A9 93 78 95 83 
A10 145 132 138 114 
A11 90 93 94 88 
A12 101 102 99 96 
A13 91 83 103 82 
A14 99 79 79 122 
A15 115 104 83 74 
A16 135 158 152 146 
A17 119 98 105 100 
A18 128 118 124 105 
A19 134 136 117 108 
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A20 118 96 124 113 
A21 93 97 94 100 
A22 157 158 152 150 
A23 158 113 109 81 
A24 251 214 226 193 
A25 109 86 93 88 
A26 112 119 119 140 
A27 106 87 121 110 
A28 113 108 92 96 
A29 85 98 88 175 
A30 128 94 113 98 
A31 98 94 93 90 
A32 140 89 88 91 
A33 110 119 108 102 
A34 134 115 119 112 
A35 105 130 122 133 
A36 121 108 132 118 
A37 81 154 113 126 
A38 119 96 123 132 
A39 95 96 110 172 
A40 82 85 88 84 
A41 144 121 121 110 
A42 165 127 104 119 
A43 113 102 94 84 
A44 128 112 119 94 
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A45 104 142 145 136 
A46 99 110 101 97 
A47 157 128 116 121 
A48 143 126 113 138 
A49 149 90 72 66 
A50 82 142 142 166 
A51 106 145 132 118 
A52 132 101 109 105 
A53 116 78 95 111 
A54 90 94 111 102 
A55 145 131 155 113 
MEAN ± SE 119.181±3.914 112.545±3.41 113.290±3.447 112.345±3.51 
P-Value Vs Base Value by One 
Way ANOVA *** *** *** 
 
P Value <0.001 *** = Statistically Significant 
In the whole group Mean ±SE of the Fasting blood sugar has decreased gradually 
from 119.181±3.914 to 112.345±3.51 during the therapy. 
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Table 25 below shows the values of Fasting blood sugar, for Group B (Metformin+ a 
Sulphonyl urea+SGLT2-I) patients, after every month of taking metformin + a 
sulphonyl urea +SGLT2-I keeping the first value as the base value 
Table 25 
Effect of Group B on Fasting Blood Sugar 
( n=50) 
PATIENT ID BASE REVIEW 1 REVIEW 2 REVIEW 3 
B1 162 108 113 98 
B2 160 111 116 107 
B3 211 119 98 96 
B4 169 100 98 94 
B5 195 180 142 108 
B6 106 111 105 98 
B7 138 128 115 124 
B8 273 222 155 173 
B9 261 192 155 126 
B10 191 165 136 122 
B11 285 214 173 158 
B12 104 123 101 98 
B13 184 153 127 111 
B14 201 121 130 103 
B15 200 137 113 118 
B16 85 145 122 92 
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B17 163 123 110 109 
B18 185 141 133 110 
B19 156 133 102 90 
B20 157 118 121 105 
B21 180 156 114 98 
B22 162 144 118 92 
B23 110 114 126 98 
B24 201 165 148 102 
B25 162 109 77 101 
B26 130 107 91 83 
B27 145 112 156 125 
B28 98 101 116 107 
B29 106 101 110 104 
B30 85 98 96 101 
B31 134 106 119 102 
B32 162 153 128 126 
B33 174 126 125 108 
B34 124 132 128 116 
B35 133 146 101 96 
B36 195 176 144 128 
B37 182 153 112 111 
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P Value <0.001 *** = Statistically Significant 
In the whole group Mean ±SE of the Fasting blood sugar has decreased significantly 
from166.08±6.771 to 108.54±2.331 during the therapy 
 
 
 
B38 104 163 101 88 
B39 158 126 103 98 
B40 118 102 109 100 
B41 273 186 122 109 
B42 101 80 67 110 
B43 165 113 122 109 
B44 202 173 133 112 
B45 195 180 117 102 
B46 188 153 112 94 
B47 252 145 129 145 
B48 166 128 133 111 
B49 148 116 121 102 
B50 165 123 145 109 
MEAN ±SE 166.08±6.771 136.62±4.378 119.76±2.816 108.54±2.331 
P-Value Vs Base Value by One 
Way ANOVA 
*** *** *** 
SGLT2 Inhibitors in NIDDM  Page 118 
 
Table 26 shows the values of Post Prandial blood sugar, for Group A (Metformin & a 
Sulphonyl urea) patients, after every month of taking metformin & a sulphonyl urea 
keeping the first value as the base value. 
Table 26 
Effect of Group A on Post Prandial Blood Sugar 
( n=55) 
PATIENT ID BASE REVIEW I REVIEW II REVIEW III 
A1 91 105 104 96 
A2 145 182 128 163 
A3 126 146 145 135 
A4 106 97 82 97 
A5 127 150 156 191 
A6 206 191 176 165 
A7 150 141 236 124 
A8 285 193 182 188 
A9 163 130 134 135 
A10 210 191 195 197 
A11 114 105 130 110 
A12 180 164 226 172 
A13 146 128 112 118 
A14 161 178 154 202 
A15 98 138 121 96 
A16 143 187 160 161 
A17 170 146 168 167 
A18 200 183 224 159 
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A19 91 148 124 159 
A20 336 164 155 273 
A21 138 149 83 111 
A22 187 184 191 154 
A23 237 162 160 154 
A24 276 265 233 178 
A25 136 166 248 169 
A26 154 234 224 157 
A27 192 158 146 140 
A28 141 114 110 108 
A29 123 120 158 132 
A30 117 127 136 124 
A31 130 144 138 94 
A32 123 213 152 176 
A33 193 186 131 136 
A34 178 177 202 199 
A35 173 128 165 170 
A36 120 192 169 140 
A37 203 180 178 175 
A38 151 120 166 129 
A39 242 139 170 256 
A40 126 180 124 133 
A41 147 171 163 145 
A42 146 250 115 159 
A43 146 245 138 140 
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P Value <0.001 *** = Statistically Significant 
In the whole group Mean ±SE of the post prandial blood sugar has decreased 
gradually from 169.927±7.387 to 158.381±5.047during the therapy 
 
 
 
 
 
 
A44 260 243 210 200 
A45 273 206 232 221 
A46 226 176 196 199 
A47 148 197 152 144 
A48 178 136 188 201 
A49 232 166 130 129 
A50 170 151 164 180 
A51 118 241 156 142 
A52 283 130 213 210 
A53 192 125 134 173 
A54 115 179 182 153 
A55 124 220 166 172 
MEAN ± SE 169.927±7.387 168.018±5.312 162.454±5.231 158.381±5.047 
P-Value Vs Base Value by One 
Way ANOVA         *** *** *** 
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Table 27 below shows the values of Post Prandial blood sugar, for Group B 
(Metformin+ a Sulphonyl urea+ SGLT2-I) patients, after every month of taking 
metformin + a sulphonyl urea + SGLT2-I keeping the first value as the base value. 
Table 27 
Effect of Group B on Post-Prandial  Blood Sugar 
(n=50) 
PATIENT ID BASE REVIEW I REVIEW II REVIEW III 
B1 249 140 128 130 
B2 243 163 152 145 
B3 297 180 106 163 
B4 281 218 156 144 
B5 207 162 195 188 
B6 156 140 131 136 
B7 276 203 212 208 
B8 348 296 164 180 
B9 334 256 190 175 
B10 292 186 175 153 
B11 352 296 225 246 
B12 254 203 167 154 
B13 275 226 158 163 
B14 291 176 185 154 
B15 218 168 154 171 
B16 213 195 175 152 
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B17 214 183 156 142 
B18 265 210 172 152 
B19 192 176 153 136 
B20 139 146 142 148 
B21 202 212 145 158 
B22 210 183 166 142 
B23 207 196 172 155 
B24 291 235 182 152 
B25 244 166 87 157 
B26 207 225 162 145 
B27 218 185 197 152 
B28 199 163 106 132 
B29 141 158 147 132 
B30 213 186 165 162 
B31 226 176 180 159 
B32 245 198 176 198 
B33 196 291 195 164 
B34 173 100 98 110 
B35 235 210 165 154 
B36 216 228 173 162 
B37 274 186 154 145 
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B38 256 201 165 173 
B39 254 247 167 148 
B40 246 202 164 149 
B41 325 210 186 185 
B42 193 156 138 176 
B43 253 186 199 167 
B44 253 202 176 132 
B45 293 244 165 148 
B46 256 198 222 174 
B47 314 186 186 193 
B48 323 214 176 172 
B49 205 183 172 154 
B50 199 176 169 165 
MEAN ±SE 243.26±7.086 196.52±5.392 165.02±3.953 159.1±3.146 
P-Value Vs Base Value by One 
Way ANOVA       *** *** *** 
 
P Value <0.001 *** = Statistically Significant 
In the whole group Mean ± SE of the post prandial blood sugar has decreased 
significantly from 243.26±7.086 to 159.1±3.146 during the therapy. 
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Table 28 shows the values of Glycosylated Haemoglobin (HbA1c), for Group A 
(Metformin & a Sulphonyl urea) patients, after every three months of taking 
metformin & a sulphonyl urea keeping the first value as the base value. 
Table 28 
Effect of Group A on HbA1c 
(n=55) 
PATIENT ID BASE REVIEW I REVIEW II 
A1 6.5 6.7 6.5 
A2 6.3 6.5 6.5 
A3 6.8 7 6.8 
A4 6.4 5.8 5.6 
A5 6.1 6.5 6.3 
A6 6 6.5 6.2 
A7 6.8 7 6.5 
A8 6.8 6.5 6.5 
A9 7 6.5 6.3 
A10 7.5 6.8 6.2 
A11 6.8 6.7 6.5 
A12 7.5 7.2 7 
A13 6.5 6.3 6.2 
A14 7.4 7.1 7.3 
A15 6.3 6.3 6.8 
A16 8 8.4 8 
A17 6.4 6.4 6.6 
A18 7.1 7.1 7 
A19 7.3 7.3 6.8 
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A20 7.2 6.5 6.4 
A21 6.5 6.2 5.9 
A22 7.9 7.6 7.6 
A23 8.5 8.2 7.5 
A24 8.9 8.5 7.4 
A25 6 6.5 6.5 
A26 6.5 6.5 6.8 
A27 6.9 6.7 6.7 
A28 6.6 6 6.2 
A29 6.8 7.1 7.8 
A30 6.5 6.3 5.8 
A31 6.6 6.2 6.2 
A32 6.4 6.2 6.6 
A33 7.1 7 6.8 
A34 7.3 7.5 7 
A35 6.8 7 7 
A36 6.5 6.9 7.3 
A37 8.2 7.7 7.5 
A38 7.5 8.3 7.3 
A39 8.6 8.4 7.9 
A40 6.3 6 6.2 
A41 6.8 6.5 6.3 
A42 6 6.2 6.4 
A43 7.4 7.8 7.2 
A44 6.4 6.7 6.2 
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A45 7 7.2 6.9 
A46 6.8 6.5 6.6 
A47 6.9 6.7 6.4 
A48 6.4 7.4 7.2 
A49 7.5 7.4 6.7 
A50 7.4 7.1 7.6 
A51 7.2 7.2 7.5 
A52 7.8 7.6 7.2 
A53 6.3 6.5 6.4 
A54 6.1 6.6 6.6 
A55 7.2 7.3 7.2 
MEAN ± SE 6.95±0.090 6.92±0.087 6.77±0.073 
P-Value Vs Base Value by One 
Way ANOVA     *** *** 
 
 P Value <0.001 *** = Statistically Significant 
In the whole group Mean±SE of the Glycosylated Haemoglobin (HbA1c) has 
decreased gradually from 6.95±0.090 to 6.77±0.073 during the therapy. 
 
 
 
 
 
 
 
SGLT2 Inhibitors in NIDDM  Page 127 
 
Table 29 below shows the values of Glycosylated Haemoglobin (HbA1c), for Group B 
(Metformin+ a Sulphonyl urea+SGLT2-I) patients, after every three months of taking 
metformin + a sulphonyl urea +SGLT2-I keeping the first value as the base value 
Table 29 
Effect of Group B on HbA1c 
(n=50)  
PATIENT ID BASE REVIEW I REVIEW II 
B1 7.8 7.1 6.7 
B2 7.1 6.7 6.2 
B3 8.2 6.8 6.7 
B4 9.1 7.8 7.4 
B5 8.3 7.9 6.5 
B6 6.7 6.3 5.7 
B7 8.4 7.6 6.2 
B8 9.6 8.2 7.5 
B9 9.7 8.5 7 
B10 8.2 7.3 6.8 
B11 9.4 8.1 6.9 
B12 8.8 7.5 7 
B13 8.4 7.2 6.9 
B14 10.9 9.1 7.6 
B15 7.5 6.9 6.5 
B16 7.5 6.5 6.3 
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B17 8.2 7.4 7 
B18 8.8 7.9 7.1 
B19 7.4 6.8 6.5 
B20 7.1 7 6.8 
B21 7.2 6.8 6.5 
B22 6.8 6.2 6.5 
B23 7.7 7.2 6.9 
B24 7.5 7 6.5 
B25 9 8.2 7.1 
B26 8.2 7.3 6.5 
B27 7.8 7.6 7.6 
B28 6.8 7.1 6.6 
B29 7.4 7.1 6.8 
B30 6.5 6.8 6.3 
B31 7.5 7.2 6.6 
B32 7.8 7 7 
B33 8.5 7.8 6.5 
B34 9.6 6.5 6.4 
B35 8.4 7.5 7.5 
B36 8.6 7.9 6.4 
B37 7.5 7 6.8 
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B38 8.2 7.5 7.1 
B39 6.9 6.2 6.4 
B40 7.8 6.5 6.2 
B41 9.8 7.7 7 
B42 7.2 6.5 6.7 
B43 7.8 7 7 
B44 8.3 7.6 6.4 
B45 9.4 7.6 6.8 
B46 7.9 7.3 6.2 
B47 9.3 8 6.8 
B48 7.9 7 6.5 
B49 7.4 7 6.5 
B50 8.1 7.2 7 
MEAN ±SE 8.118±0.131 7.278±0.084 6.728±0.055 
P-Value Vs Base Value by One 
Way ANOVA *** *** 
 
P Value <0.001 *** = Statistically Significant 
In the whole group Mean±SE of the Glycosylated Haemoglobin (HbA1c) has 
decreased significantly from 8.118±0.131 to 6.728±0.055 during the therapy. 
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Table 30 shows the values of Body weight in Kg, for Group A (Metformin & a 
Sulphonyl urea) patients, after every month of taking metformin & a sulphonyl urea 
keeping the first value as the base value. 
Table 30 
Effect of Group A on Body Weight in Kg 
(n=55) 
PATIENT ID BASE REVIEW I REVIEW II REVIEW III 
A1 68 67 65.3 66 
A2 64 64 63 62 
A3 105.55 103 101 98 
A4 78 77 77 75 
A5 62 61.7 60.2 59.3 
A6 72 72 71 69.7 
A7 66.85 68.3 69.1 68.8 
A8 59.75 59 58.5 56.7 
A9 64 63 62 62 
A10 68 67 67 65 
A11 82 81.3 79.2 78.2 
A12 52.4 52 52 51.2 
A13 76 75 75 74.2 
A14 79 81 80 80 
A15 54 56 54 54 
A16 66.2 66 67.4 67 
A17 49.65 49.65 49 51.3 
A18 85.25 86 84 83 
A19 66 66 65 66 
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A20 58 58 58 58 
A21 61.6 62.75 61 61 
A22 77 76 75 75 
A23 58 57.4 56.6 56 
A24 78 77.8 77 76 
A25 75 75 75 74 
A26 55.5 55.8 55 57 
A27 48 48 48 48.8 
A28 66 64.24 65 65 
A29 62 64.45 66 65 
A30 53 53 52 52 
A31 72 74 74 75 
A32 61 62 63.9 64.85 
A33 53 53 53 53 
A34 72 70 71 71.5 
A35 55.9 55 55 55 
A36 64 64 65.3 65 
A37 74 75.3 77 76.4 
A38 56 58 57 56 
A39 64 64 64 65 
A40 74 74 73 72 
A41 63.3 64 64 63 
A42 49 48 49 50 
A43 53.75 53.1 53 53 
A44 78 77.4 77 76 
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A45 103.5 101 100 99.5 
A46 63 62.4 62 60.5 
A47 66 66 61 61 
A48 78 77 74 73 
A49 58 57.8 57 56.4 
A50 65 65 65 64 
A51 53.5 53.8 55 55.4 
A52 55 54 54 52 
A53 61 61 62 60 
A54 61 61 60 58.5 
A55 69.9 68.85 67.6 66 
MEAN ± SE 66.083±1.583 65.946±1.583 65.492±1.542 65.040±1.458 
P-Value Vs Base Value by 
One Way ANOVA *** *** *** 
 
P Value <0.001 *** = Statistically Significant 
In the whole group Mean±SE of the Body weight has decreased gradually from 
66.083±1.583to 65.040±1.458 during the therapy. 
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Table 31 shows the values of Body weight in Kg, for Group B 
(Metformin+aSulphonyl urea+SGLT2-I) patients, after every month of taking 
metformin + a sulphonyl urea +SGLT2I keeping the first value as the base value. 
Table 31 
Effect of Group B on Body Weight in Kg 
(n=50) 
PATIENT ID BASE REVIEW I REVIEW II REVIEW III 
B1 58 56 55 54 
B2 63.55 63.25 62 62 
B3 63 63 63 52 
B4 57.5 56 57 57 
B5 53.15 51.55 50 49 
B6 63 63 62 61 
B7 84.05 81.05 79 78 
B8 117.3 115 113.5 111 
B9 84.6 81.7 79.2 78 
B10 55.9 55.2 54 53 
B11 69.5 67.5 66 65.4 
B12 76 77 74.24 72 
B13 73 71 68.9 67.5 
B14 91.8 90 89 87 
B15 59 54.5 54 50.3 
B16 74.5 72.3 71 70 
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B17 87 85 82 81 
B18 76 74.5 73.2 71.3 
B19 72 69 68.3 66.5 
B20 79.2 77.8 76.5 74.9 
B21 67.5 66 64.6 63 
B22 75 73.3 71.8 70 
B23 74.4 73 71.6 68.3 
B24 92 91.3 88.5 87.2 
B25 58.8 57.6 55 54 
B26 74 72 71.9 67 
B27 68 66.2 65 63.7 
B28 63 62 61.3 60 
B29 58.15 56.3 54.7 53 
B30 74.5 73.2 71 68.4 
B31 83 81.9 80.2 78 
B32 77 75.6 76 75 
B33 92 90 88.6 87 
B34 63 61 58.5 55 
B35 98 96 94.4 92 
B36 88 87 85.3 85 
B37 75 73.2 71.1 70 
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B38 79 78 76.2 74 
B39 65.4 64 63.3 63 
B40 73 71 69.4 67.6 
B41 77 74 72.6 71 
B42 67.5 66.7 65 63.8 
B43 76 75.4 74 72.2 
B44 91 89.4 88 86.5 
B45 75 73.2 73 72.3 
B46 72 71.2 70 68.4 
B47 78 77.3 75.3 74 
B48 82 80.2 77.6 77 
B49 69 68.2 66.6 65 
B50 74 72.1 71 69.4 
MEAN ±SE 74.366±1.716 72.813±1.703 71.386±1.672 69.634±1.689 
P-Value Vs Base Value by One 
Way ANOVA *** *** *** 
 
P Value <0.001 *** = Statistically Significant 
In the whole group Mean±SE of the Body weight has decreased significantly from 
74.366 ± 1.716 to 69.634 ± 1.689 during the therapy. 
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Comparative Mean Reduction in FPG of Group A and Group B 
 
Table 32  shows in Group A (Metformin + a Sulphonyl urea) patients (n=55), the 
mean value change of fasting blood sugar at the base line was 119.181 ±3.914 and 
after treatment for a mean period of 6 months, it was observed 112.345 ±3.51. 
In Group B (Metformin+aSulphonyl urea+SGLT2-I) patients (n=50) the mean value 
change of fasting blood sugar at the base line was 166.08 ±6.77and after treatment for 
a mean period of 6 months, it was observed 108 ± 2.33. 
In Group A (Metformin + a Sulphonyl urea) patients (n=55), the percentage mean 
change value is 5.70% 
In Group B (Metformin+a Sulphonyl urea+SGLT2-I) patients (n=50) the percentage 
mean change value is 34.67% 
Table 32 
Mean ± SE Reduction in FPG of   
Group A and Group B   
 
Groups 
 
No. of 
patients 
Mean ± SE Change of  Group A & B in 
FPG mg/dL 
 
% mean 
Reduction Base  Rev I Rev II Rev III 
Group A 
Metformin+sulphonyl 
urea 
 
55 
119.181 
± 
3.914 
112.545 
± 
3.410 
113.290 
± 
3.447 
112.345 
± 
3.51 
 
5.70 
Group B 
Metformin+sulphonyl 
urea + SGLT2-I 
 
50 
166.08 
 ± 
6.77 
136.6  
± 
4.378 
119.7  
± 
2.816 
108  
± 
2.33 
 
34.67 
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Fig.  19 
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Comparative Mean Reduction in PPPlasma Glucose of  Group A & B 
 
Table 33 shows in Group A (Metformin + a Sulphonyl urea) patients (n=55), the 
mean value change of Post Prandial blood sugar at the base line was169.927 ±7.387 
and after treatment for a mean period of 6 months, it was observed 158.381±5.047. 
In Group B (Metformin+aSulphonyl urea+SGLT2-I) patients (n=50) the mean value 
change of Post Prandial blood sugar at the base line was 243.2±7.086 and after 
treatment for a mean period of 6 months, it was observed 159.1±3.146. 
In Group A (Metformin + a Sulphonyl urea) patients (n=55), the percentage mean 
change value is 6.79% 
In Group B (Metformin+aSulphonyl urea+SGLT2-I) patients (n=50) the percentage 
mean change value is 34.58% 
Table 33 
Mean ± SE Reduction in PostPrandial (PP) Plasma Glucose of 
Group A and Group B  
 
Groups 
 
No.of 
patients 
Mean ± SE Change of  Group A & B in PP 
mg/dL 
 
% mean 
Reduction Base  Rev I Rev II Rev III 
GroupA 
Metformin+sulphonyl 
urea 
 
55 
169.927 
± 
7.387 
168.018 
± 
5.312 
162.45  
± 
5.231 
158.381 
± 
5.047 
 
6.79 
GroupB 
Metformin+sulphonyl 
urea + SGLT2-I 
 
50 
243.2 
± 
7.086 
196.5 
± 
5.392 
165.02 
± 
3.953 
159.1 
± 
3.146 
 
34.58 
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Fig. 20 
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Comparative Mean Reduction in HbA1c of Group A and B 
Table 34 shows in Group A (Metformin + a Sulphonyl urea) patients (n=55), the 
mean value change of Glycosylated Haemoglobin (HbA1c) at the base line was 
6.95±0.090 and after treatment for a mean period of last 3 months, it was observed to 
be 6.77±0.073. 
In Group B (Metformin+aSulphonyl urea+SGLT2-I) patients (n=50) the mean value 
change ofGlycosylated Haemoglobin (HbA1c) at the base line was 8.1±0.131 and 
after treatment for a mean period of last 3 months, it was observed to be 6.7±0.055. 
In Group A (Metformin + a Sulphonyl urea) patients (n=55), the percentage mean 
change value is 2.5% 
In Group B (Metformin+aSulphonyl urea+SGLT2-I) patients (n=50) the percentage 
mean change value is 7.28% 
Table 34 
Mean ± SE Reduction in HbA1c Value of   
Group A and Group B  
 
Groups 
 
No.of 
patients 
Mean ± SE Change of  Group A & B in 
HbA1c in % 
 
% mean 
Reduction Base Rev I Rev II 
GroupA 
Metformin+sulphonyl 
urea 
 
55 
 
6.95±0.090 
 
6.92±0.087 
 
6.77±0.073 
 
2.5 
Group B 
Metformin+sulphonyl 
urea + SGLT2-I 
 
50 
 
8.1±0.131 
 
7.2± 0.084 
 
6.7±0.055 
 
7.28 
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Figure 21 
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Comparative Mean Reduction in Body Weight of Group A and B 
Table 35 shows in Group A (Metformin + a Sulphonyl urea) patients (n=55), the 
mean value change of Body weight in Kg at the base line was 66.083±1.583 and after 
treatment for a mean period of 6 months, it was observed 65.040±1.458. 
In Group B (Metformin+a Sulphonyl urea+SGLT2-I) patients (n=50) the mean value 
change of Body weight in Kg at the base line was 74.366±1.716 and after treatment 
for a mean period of 6 months, it was observed 69.63±1.689. 
In Group A (Metformin + a Sulphonyl urea) patients (n=55), the percentage mean 
change value is 1.57% 
In Group B (Metformin+aSulphonyl urea+SGLT2-I) patients (n=50) the percentage 
mean change value is 6.28% 
Table 35 
Mean ± SE Reduction in Body Weight in Kg of 
Group A and Group B  
 
Groups 
 
No.of 
patients 
Mean ± SE Change of  Group A & B in 
Body weight in kg 
% mean 
Reduction 
Base  Rev I Rev II Rev III 
Group A 
Metformin+sulphonyl 
urea 
 
55 
 
66.083± 
1.583 
 
65.946± 
1.583 
 
65.492± 
1.542 
 
65.040± 
1.458 
 
1.57 
Group B 
Metformin+sulphonyl 
urea + SGLT2-I 
 
50 
 
74.366± 
1.716 
 
72.8± 
1.703 
 
71.3± 
1.672 
 
69.63± 
1.689 
 
6.28 
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Figure 22 
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12.  CONCLUSION 
 
 This study included 105, T2DM patients of which, patients in the age group of 
21 to 30 yrs on one end and 71 to 80 yrs on the other were a bare minimal on 
both the groups. Further the social habits, food habits being a vegan or non-
vegetarian were also equally distributed amongst the two groups. About 
familial history of Diabetes with the patients, it was 73% in Group A and 72% 
in Group B. Patients with normal weight were 22% in Group A and 16% in 
Group B of the Body Mass Index. 5% patients were under Class III category 
of obesity in Group A whereas it was 6% in Group B. All the above 
parameters are placed of equal distribution, thereby variables are kept at a bare 
minimum not jeopardizing the observed results in any way 
 
 F. P. G. values showed a reduction of 5.7% from base value in Group A; 
whereas the same was showing  a significant 34.64% reduction in Group B 
patients 
 
 The post prandial glucose measurement showed a 6.79% reduction in Group 
A and 34.58% reduction in Group B patients 
 
 The HbA1c values showed a 2.59%reduction in Group A and a very 
significant 7.28% reduction in Group B cases 
 
 Ultimately the reduction in Body Mass Index was 1.57%in Group A and 
6.28% in Group B patients  
 
 The outcome of this study clearly shows that addition of a SGLT2 inhibitor 
drug to the conventional oral regime of type II diabetes with metformin and a 
sulphonyl urea has a marked and significant advantage over the biguanide + 
sulphonyl urea only combination considering all the parameters that showa 
better and significant control of the blood glucose level and the Body Mass 
Index. 
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 Hence T2DM may conveniently be treated with metformin and a sulphonyl 
urea with the addition of a SGLT2 Inhibitor for a significantly improved life 
of patients. 
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PATIENT INFORMED CONSENT FORM 
PROFORMA –I 
PATIENT NAME :       DATE: 
AGE:         SEX: 
I was explained about the description of the research study and they 
have answered all the questions I have at this time. 
I freely volunteer to participate in this study. I understand that I need 
not have to take part in this study and that my refusal to participate will 
involve no penalty. Further I understand that I am free to discontinue 
participation from this study at any time. 
 
Clinician’s name:                      Signature of the patient 
mwptpf;fg;gl;l KbT 
Nehahspapd; ngah;:       Njjp : 
taJ:          ghypdk; : 
vdf;F Muha;r;rp Ma;T tpsf;fk; gw;wp KOtJkhf tpsf;fpaNjhL> ehd; 
Nfl;l midj;J re;Njfq;fSf;Fk;, jpUg;jpfukhf gjpy; mspj;jdh;. 
 ehd; KOkdjhf ,e;j Ma;tpy; gq;Nfw;f rk;kjpf;fpNwd;. ,e;j Ma;tpy; vd; 
clw;rk;ke;jg;gl;l gq;Nfw;G vJTk; ,y;iy vdTk;> ,jpy; ehd; gq;Nfw;f;f 
kWg;gjpdhy; vdf;F mguhjk; vJTk; ,y;iy vdTk;> kw;Wk; ,e;j Ma;tpy; 
,Ue;J ve;j NeuKk; ehd; tpyfpf;nfhs;s vdf;F chpik cz;L vd;gijAk;, ehd; 
Ghpe;J nfhz;Nld;. 
 
kUj;Jthpd; ngah;       Nehahspapd; ifnahg;gk; 
 
PROFORMA – II 
PATIENT DETAILS 
PATIENT ID:      
GENDER: M/F   AGE:  D.O.B: 
MARITAL STATUS:   
REVIEW ON 
 
CONSULTANT NAME: 
STUDY GROUP: A           B             
GENERAL INFORMATION: 
HT:   WT:   BMI:   IBW: 
 HISTORYOF ILLNESS 
TIME OF ONSET / YEAR DIAGNOSED: 
DURATION: 
FAMILY HISTORY OF DIABETES: 
Father/Mother/Siblings/Others/Nil 
HYPERTENSION: YES / NO   DURATION: 
PAST MEDICAL HISTORY: 
 
PAST MEDICATION HISTORY: 
 
SOCIAL HISTORY: 
HABITS PREVIOUS NOW 
  REGULAR IRREGULAR 
Alcohol    
Tobacco Smoking    
Tobacco Chewing    
Veg / Non-Veg    
PHYSICAL ACTIVITY: 
COMPLAINTS: 
 
DIAGNOSIS: 
      
PROFORMA  III 
DIABETIC PROFILE 
S.No. Test Reference Value mg/dL Results mg/dL 
   R1 R2 R3 R4 R5 R6 
1. Fasting 70-100       
2. PP <140       
3. GRBS Below 200       
4. HbA1c 6-7 % good control 
7-8% fair control 
8-10 % unsatisfactory control 
Above 10% poor control 
      
 
PROFORMA  IV 
 
MEDICATION CHART: 
S.No. Brand Name Generic Name Dose Route Frequency Prescribed During Review 
No. 
      R1 R2 R3 R4 R5 R6 
Date        
1.            
2.            
3.            
4.            
5.            
6.            
7.            
8.            
9.            
10.            
11.            
12.            
13.            
14.            
15.            
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
